CA2622904A1 - Self-assembling nanoparticles for the treatment of vascular diseases - Google Patents
Self-assembling nanoparticles for the treatment of vascular diseases Download PDFInfo
- Publication number
- CA2622904A1 CA2622904A1 CA002622904A CA2622904A CA2622904A1 CA 2622904 A1 CA2622904 A1 CA 2622904A1 CA 002622904 A CA002622904 A CA 002622904A CA 2622904 A CA2622904 A CA 2622904A CA 2622904 A1 CA2622904 A1 CA 2622904A1
- Authority
- CA
- Canada
- Prior art keywords
- nanoparticle
- composition
- nanoparticles
- self
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 192
- 238000011282 treatment Methods 0.000 title description 8
- 208000019553 vascular disease Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 claims abstract description 105
- 230000027455 binding Effects 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 239000007924 injection Substances 0.000 claims abstract description 22
- 238000002347 injection Methods 0.000 claims abstract description 22
- 239000007972 injectable composition Substances 0.000 claims abstract description 10
- 238000009825 accumulation Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 229910052751 metal Inorganic materials 0.000 claims description 19
- 239000002184 metal Substances 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 17
- 238000001338 self-assembly Methods 0.000 claims description 12
- 150000002739 metals Chemical class 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 10
- 229920000431 shape-memory polymer Polymers 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940127217 antithrombotic drug Drugs 0.000 claims 1
- 239000002654 heat shrinkable material Substances 0.000 claims 1
- 229940045847 receptor mimetic Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 238000011065 in-situ storage Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 38
- 229920000642 polymer Polymers 0.000 description 35
- -1 etc.) Substances 0.000 description 34
- 239000002245 particle Substances 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 31
- 229920000867 polyelectrolyte Polymers 0.000 description 26
- 229920001577 copolymer Polymers 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 238000010168 coupling process Methods 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 239000002088 nanocapsule Substances 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 238000010438 heat treatment Methods 0.000 description 17
- 239000010408 film Substances 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- 230000005291 magnetic effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000017 hydrogel Substances 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 13
- 229910001000 nickel titanium Inorganic materials 0.000 description 13
- 230000003993 interaction Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 238000005530 etching Methods 0.000 description 11
- 229920000447 polyanionic polymer Polymers 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 9
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000000151 deposition Methods 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 230000003966 vascular damage Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102100037362 Fibronectin Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 6
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000000415 inactivating effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000011257 shell material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229910045601 alloy Inorganic materials 0.000 description 5
- 239000000956 alloy Substances 0.000 description 5
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
- 229920000570 polyether Polymers 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000004544 sputter deposition Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 102000008607 Integrin beta3 Human genes 0.000 description 4
- 108010020950 Integrin beta3 Proteins 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100030416 Stromelysin-1 Human genes 0.000 description 4
- 101710108790 Stromelysin-1 Proteins 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000003446 memory effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 3
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102000013818 Fractalkine Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000000788 chromium alloy Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000005294 ferromagnetic effect Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052741 iridium Inorganic materials 0.000 description 3
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 239000012781 shape memory material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 2
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 2
- CEGXZKXILQSJHO-KODRXGBYSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC(F)=O CEGXZKXILQSJHO-KODRXGBYSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 101710091342 Chemotactic peptide Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229920002943 EPDM rubber Polymers 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 108010007267 Hirudins Chemical class 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000004019 antithrombin Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010024668 arginyl-glutamyl-aspartyl-valine Proteins 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 229910001566 austenite Inorganic materials 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- XXXSJQLZVNKRKX-YQRDHHIGSA-N depreotide Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)C(=O)N(C)[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 XXXSJQLZVNKRKX-YQRDHHIGSA-N 0.000 description 2
- 229950010726 depreotide Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 229920001746 electroactive polymer Polymers 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical class C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- 229960002437 lanreotide Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910000734 martensite Inorganic materials 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- MIFGOLAMNLSLGH-SXUUOERCSA-N methyl 5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-SXUUOERCSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- GICWIDZXWJGTCI-UHFFFAOYSA-I molybdenum pentachloride Chemical compound Cl[Mo](Cl)(Cl)(Cl)Cl GICWIDZXWJGTCI-UHFFFAOYSA-I 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 108010008217 nidogen Proteins 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000012704 polymeric precursor Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000005049 silicon tetrachloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002207 thermal evaporation Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229910000314 transition metal oxide Inorganic materials 0.000 description 2
- 108010075124 tuftsin receptor Proteins 0.000 description 2
- KPGXUAIFQMJJFB-UHFFFAOYSA-H tungsten hexachloride Chemical compound Cl[W](Cl)(Cl)(Cl)(Cl)Cl KPGXUAIFQMJJFB-UHFFFAOYSA-H 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- JJTUDXZGHPGLLC-ZXZARUISSA-N (3r,6s)-3,6-dimethyl-1,4-dioxane-2,5-dione Chemical compound C[C@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-ZXZARUISSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- SJDLIJNQXLJBBE-UHFFFAOYSA-N 1,4-dioxepan-2-one Chemical compound O=C1COCCCO1 SJDLIJNQXLJBBE-UHFFFAOYSA-N 0.000 description 1
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- XTNWJMVJVSGKLR-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CCNS(=O)(=O)C1=CC=CC=C1 XTNWJMVJVSGKLR-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FXXZYZRHXUPAIE-UHFFFAOYSA-N 6,6-dimethyl-1,4-dioxan-2-one Chemical compound CC1(C)COCC(=O)O1 FXXZYZRHXUPAIE-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108010012927 Apoprotein(a) Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 150000004006 C-nitroso compounds Chemical class 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical compound C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 108010083701 Chemokine CCL22 Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- VKPYUUBEDXIQIB-QBPWRKFFSA-N Ciprostene Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@]21C VKPYUUBEDXIQIB-QBPWRKFFSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229910015221 MoCl5 Inorganic materials 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- MNNBCKASUFBXCO-YFKPBYRVSA-N N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)S MNNBCKASUFBXCO-YFKPBYRVSA-N 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229940124090 Platelet-derived growth factor (PDGF) receptor antagonist Drugs 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 150000004007 S-nitroso compounds Chemical class 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010083387 Saralasin Proteins 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229910010066 TiC14 Inorganic materials 0.000 description 1
- 229910010380 TiNi Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100026260 Titin Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229910021552 Vanadium(IV) chloride Inorganic materials 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 229940127508 Vitamin K Inhibitors Drugs 0.000 description 1
- 229910003091 WCl6 Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000001015 X-ray lithography Methods 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- GYKFWCDBQAFCLJ-RTWAWAEBSA-N [(2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 GYKFWCDBQAFCLJ-RTWAWAEBSA-N 0.000 description 1
- WBWJXRJARNTNBL-UHFFFAOYSA-N [Fe].[Cr].[Co] Chemical compound [Fe].[Cr].[Co] WBWJXRJARNTNBL-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000000217 alkyl group Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(III) oxide Inorganic materials O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 102000036203 calcium-dependent phospholipid binding proteins Human genes 0.000 description 1
- 108091011005 calcium-dependent phospholipid binding proteins Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000002134 carbon nanofiber Substances 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- UPHIPHFJVNKLMR-UHFFFAOYSA-N chromium iron Chemical compound [Cr].[Fe] UPHIPHFJVNKLMR-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229950009522 ciprostene Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229950000308 clentiazem Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- XQGZSYKGWHUSDH-UHFFFAOYSA-N dazoxiben Chemical compound C1=CC(C(=O)O)=CC=C1OCCN1C=NC=C1 XQGZSYKGWHUSDH-UHFFFAOYSA-N 0.000 description 1
- 229950008000 dazoxiben Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-O diazenium Chemical compound [NH2+]=N RAABOESOVLLHRU-UHFFFAOYSA-O 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000000609 electron-beam lithography Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229920005680 ethylene-methyl methacrylate copolymer Polymers 0.000 description 1
- 238000001900 extreme ultraviolet lithography Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- IVJISJACKSSFGE-UHFFFAOYSA-N formaldehyde;1,3,5-triazine-2,4,6-triamine Chemical compound O=C.NC1=NC(N)=NC(N)=N1 IVJISJACKSSFGE-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000002241 glass-ceramic Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 229910001026 inconel Inorganic materials 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000000707 layer-by-layer assembly Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
- 229960002006 linsidomine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000011553 magnetic fluid Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 239000002048 multi walled nanotube Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 239000002101 nanobubble Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910000484 niobium oxide Inorganic materials 0.000 description 1
- URLJKFSTXLNXLG-UHFFFAOYSA-N niobium(5+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Nb+5].[Nb+5] URLJKFSTXLNXLG-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- NRNFFDZCBYOZJY-UHFFFAOYSA-N p-quinodimethane Chemical group C=C1C=CC(=C)C=C1 NRNFFDZCBYOZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920003227 poly(N-vinyl carbazole) Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000090 poly(aryl ether) Polymers 0.000 description 1
- 229920003055 poly(ester-imide) Polymers 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920002480 polybenzimidazole Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001228 polyisocyanate Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006124 polyolefin elastomer Polymers 0.000 description 1
- 229920001955 polyphenylene ether Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 229920006215 polyvinyl ketone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- MLGWTHRHHANFCC-UHFFFAOYSA-N prop-2-en-1-amine;hydrochloride Chemical compound Cl.NCC=C MLGWTHRHHANFCC-UHFFFAOYSA-N 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 description 1
- 229950006674 ridogrel Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920003031 santoprene Polymers 0.000 description 1
- PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 1
- 229960004785 saralasin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002109 single walled nanotube Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 229950001172 sulotroban Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IEXRMSFAVATTJX-UHFFFAOYSA-N tetrachlorogermane Chemical compound Cl[Ge](Cl)(Cl)Cl IEXRMSFAVATTJX-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 238000007736 thin film deposition technique Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- JTJFQBNJBPPZRI-UHFFFAOYSA-J vanadium tetrachloride Chemical compound Cl[V](Cl)(Cl)Cl JTJFQBNJBPPZRI-UHFFFAOYSA-J 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/12—Shape memory
Abstract
The present invention is directed to the formation of structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling nanoparticles is provided. The self-assembling nanoparticles include: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which cause preferential binding and accumulation of the nanoparticles at one or more targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.
Description
SELF-ASSEMBLED ENDOVASCULAR STRUCTURES
FIELD OF THE INVENTION
[0001] This invention relates to self-assembled endovascular structures, which are useful for the treatment of a variety of diseases and conditions.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] This invention relates to self-assembled endovascular structures, which are useful for the treatment of a variety of diseases and conditions.
BACKGROUND OF THE INVENTION
[0002] The present state of the art concerning the deployment and placement of endovascular medical devices is challenged by profile and delivery issues. For example, before a stent is delivered and positioned appropriately, the specific target site must first be detected and characterized using complex imaging and sensing procedures.
This is then followed by cumbersome tracking and delivery procedures using guidewires, catheters, and various other devices. These procedures often have to be repeated to achieve the desired result. Hence, there is great expense associated with these procedures.
This is then followed by cumbersome tracking and delivery procedures using guidewires, catheters, and various other devices. These procedures often have to be repeated to achieve the desired result. Hence, there is great expense associated with these procedures.
[0003] Moreover, therapeutic devices capable of intervention at the molecular level, such as Boston Scientific's paclitaxel-based drug-eluting stent, have shown significant potential for disease management. However, while effective, such devices are complex and expensive.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0004] The above and other challenges have intensified the need for inexpensive endovascular constructs that are specific, efficacious, and able to be deployed with a high degree of freedom and precision.
[0005] In this regard, the present invention is directed to the formation of endovascular structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease management.
[0006] According to one aspect of the invention, an injectable composition comprising self-assembling nanoparticles is provided. The self-assembling nanoparticles include: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which cause preferential binding and accumulation of the nanoparticles at one or more I
targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.
targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.
[0007] Specific examples of applications of the present invention include the in situ formation of endovascular patches for vulnerable plaque and aneurysmal management, expandable stents for increasing blood flow and maintaining vessel patency, contractible patches for congestive heart failure, drug delivery structures, and scaffolding for tissue engineering. However, the application of this platform technology is ubiquitous and many other applications will immediately become apparent to those of ordinary skill in the art upon reading the detailed description and claims to follow.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0008] A more complete understanding of the present invention is available by reference to the following detailed description of numerous aspects and embodiments of the invention. The detailed description of the embodiments which follows is intended to illustrate but not limit the invention.
[0009] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
[0010] In accordance with a first aspect of the invention, compositions are provided that contain self-assembling nanoparticles. These nanoparticles, in turn, coinprise the following: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which result in the preferential binding and accumulation of the nanoparticles at one or more target locations in the body, and (c) first and second interparticle binding ligands attached to the nanoparticle, which preferentially bind to one another, wherein the first and second interparticle binding ligands can be the same or different.
[0011] Compositions in accordance with the present invention may be injected via various routes including intravascular injection (e.g., intravenous injection, intraarterial injection, intracoronary injection, intracardiac injection, etc.), intramuscular injection, subcutaneous injection, and intraperitoneal injection routes, among others.
Injection may proceed via various known medical devices including syringes, venous drug delivery catheters, arterial drug delivery catheters, and so forth. Drug deliver catheters are advantageous in certain embodiments as they facilitate more localized, less systemic, drug delivery. Various drug delivery catheter designs are known, including perfusion catheters, injection catheters, and double balloon catheters, among others.
Injection may proceed via various known medical devices including syringes, venous drug delivery catheters, arterial drug delivery catheters, and so forth. Drug deliver catheters are advantageous in certain embodiments as they facilitate more localized, less systemic, drug delivery. Various drug delivery catheter designs are known, including perfusion catheters, injection catheters, and double balloon catheters, among others.
[0012] In some embodiments, the nanoparticles are stored or rehydrated with a solution that inhibits binding between the interparticle binding ligands prior to injection. In these embodiments the nanoparticles are injected at concentrations that are low enough to prevent substantial aggregation at the time injection, with the majority of the binding occurring when the nanoparticles come into close association with each other at the assembly site (e.g., due to the presence of the tissue binding ligands on the microparticles). In other embodiments, at least one of the first and second interparticle binding ligands is activated in vivo at the one or more target locations within the body.
These features of the invention allow self-assembly of nanoparticles at the target site, while at the same time avoiding premature interparticle aggregation, e.g., prior to injection.
These features of the invention allow self-assembly of nanoparticles at the target site, while at the same time avoiding premature interparticle aggregation, e.g., prior to injection.
[0013] With respect to embodiments in which the interparticle binding ligands are activated in vivo, such activation may proceed via any suitable process. For example, one or both of the interparticle binding ligands may be inactivated by reversibly attaching the same to an inactivating moiety (e.g., a hydrophilic polymer chain, among many other choices) that prevents the interparticle binding ligands from binding to one another. The inactivating moiety is then cleaved from the ligand(s) in vivo at the one or more target locations within the body, for instance, by exposure to enzymes or to light (e.g., using a catheter) to release the inactivating moiety. See, e.g., Subr V, et al.
"Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds." J Biomater Sci Polym Ed. 1990;1(4):261-78.
"Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds." J Biomater Sci Polym Ed. 1990;1(4):261-78.
[0014] Analogously, one or both of the interparticle binding ligands may be inactivated by reversibly attaching the same to an inactivating moiety via a linkage that is thermally cleavable. (In these and other instances herein, the temperatures used are typically sufficiently low to avoid disruption of the linkage between the tissue binding ligands and the tissue at the target locations.) The inactivating moiety is then cleaved from the ligand in vivo by heat (e.g. by heating with MRI, etc., or flushing the area via catheter with a warm solution) to release the inactivating moiety. Linkages which are thermally unstable include metal coordination bonding, for instance, the linkage of acrylamide polymers to histidine groups through metal coordination bonding (See, e.g., Chen et al.
and Wang et al. below). Other examples are linkages between groups that pair to one another via multiple hydrogen bonds. Several examples of such molecules are described in Sherrington DC and Taskinen KA, "Self-assembly in synthetic macromolecular systems via multiple hydrogen bonding interactions," Clzern. Soc. Rev., 2001, 30 (2), 83-93, and include the familiar hydrogen bonding between thymine/uracil and adenine and between cytosine and guanine, as well as higher order bonding such as bonding via four hydrogen bonds using uredopyrimidinone residues. (Note that uredopyrimidinone residues bind to one another and thus represent ligands that are the same and yet bind to one another. In this regard, such ligands are also used for interparticle binding in certain embodiments of the invention.) [00151 In other embodiments, one or both of the interparticle binding ligands are embedded within a hydrogel polymer. Upon a triggering event, which makes the hydrogel polymer go from a more hydrophobic to a more hydrophilic state (which is also accompanied by swelling of the hydrogel) or which makes the hydrogel polymer go from a more hydrophilic state to a more hydrophobic state, the binding ligand may be expelled/released from the hydrogel into the biological milieu. For example, hydrogels are known that become more hydrophilic based on changes in pH, osmolality or temperature, upon application of an electric field, and so forth. See, e.g., Chatterjee, et al., Nanotech 2003 Vol. 1, Technical Proceedings of the 2003 Nanotechnology Conference and Trade Show, Volume 1, Chapter 7: Bio Micro Systems, "Electrically Triggered Hydrogels: Mathematical Models and Simulations," pp. 130 - 133;
Eichenbaum GM, et al. "pH and Ion-Triggered Volume Response of Anionic Hydrogel Microspheres." Macromolecules. 1.998 Ju128;31(1.5):5084-93; Chen et al., "Responsive hybrid hydrogels with volume transitions modulated by a titin immunoglobulin module."
Biocoqj. Chem. 2000 Sep-Oct;1.1.(5): 734-40; Coughlan DC, et al., "Effect of drug physicochemical properties on swelling/deswelling kinetics and pulsatile drug release from thermoresponsive poly(N-isopropylacrylamide) hydrogels." J Control Release. 2004 Jul 23;98(1):97-114; Molinaro G, et al. "Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials."
Biomaterials. 2002 Jul;23(13):2717-22. Wang C, et al. "Hybrid hydrogels cross-linked by genetically engineered coiled-coil block proteins." Bionaacrornolecules.
Fall;2(3):912-20. Hence, using the above hydrogel polymers as well as other currently available polymer matrices, ligand release may be triggered, for example, by local pH
change (e.g., by flushing the area with an acidic or basic solution via catheter) to ionize ionic groups in the polymer, by heating (e.g. by heating with MRI or flushing the area with a warm solution via catheter) to force a transformation of the polymer beyond a critical transition that allows hydration, or by hydrolysis/enzymatic cleavage to expose 1lydrophilic groups in the polymer. In addition to (or as an alternative to) ligand coverage and exposure, such triggerable hydrogels may also be used to retain and release drugs.
[0016] Activation of the ligand via conformation changes may also be employed, e.g., by denaturation, pH change, temperature change, and so forth.
[0017] In certain embodiments, the nanoparticles (except for portions that contain binding ligands), may be provided with a passivating, non-reactive surface.
For example, a coating of polyethylene glycol or another known surface passivating polymer may be applied to prevent protein interactions, nonspecific binding and aggregation, and so forth.
[0018] In accordance with another aspect of the invention, a kit is provided which contains at least first and second nanoparticle-containing injectable compositions. The first injectable composition comprises first self-assembling nanoparticles which comprise the following: (a) a first nanoparticle portion (b) tissue binding ligands attached to the first nanoparticle portion which result in the preferential binding and accumulation of the nanoparticles at one or more target locations in the body, and (c) first interparticle binding ligands attached to the first nanoparticle portion to promote interparticle binding. The second injectable composition comprises second self-assembling nanoparticles which comprise the following: (a) a second nanoparticle portion and (b) second interparticle binding ligands attached to the second nanoparticle portion, which preferentially bind to the first interparticle binding ligands attached to the first nanoparticle portion. The second self-assembling nanoparticles may or may not contain tissue binding ligands.
Moreover, the first and second nanoparticle portions can be of the same or of different compositions.
[0019] In this aspect of the invention, injection of the first composition results in preferential binding and accumulation of the first self-assembling nanoparticles at one or more target locations in the body, thereby forming an initial base layer. Upon subsequent injection of the second composition, the interparticle binding ligands on the second nanoparticles preferentially bind to the first interparticle binding ligands of the first nanoparticles. By alternating the injection of the first and second coinpositions, nanoparticles are assembled on the tissue in a layer-by-layer fashion with lock-and-key specificity.
[0020] If desired, a third composition can then be administered which comprises third self-assembling nanoparticles which comprise the following: (a) a third nanoparticle portion and (b) third interparticle binding ligands attached to the third nanoparticle portion, which preferentially bind to the second interparticle binding ligands of second nanoparticles. Although tissue binding ligands can be attached to the third self-assembling nanoparticles, in many embodiments, the third self-assembling nanoparticles will not comprise tissue binding ligands. The nanoparticle portions of the third self-assembling nanoparticles can be the same as or different from the nanoparticle portions of the first and second self-assembling nanoparticles. Moreover, the third interparticle binding ligands can be the same as or different from the first interparticle binding ligands.
Upon injection of the third composition, the interparticle binding ligands on the third self-assembling nanoparticles bind to those on the previously attached second self-assembling nanoparticles.
[0021] Analogous to the above, by alternating the injection of the second and third compositions, nanoparticles are assembled on the tissue in a layer-by-layer fashion.
[0022] As previously indicated, the compositions of the present invention can be used to in the treatment of a variety of diseases and conditions. "Treatment" refers to the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition. Preferred subjects (also referred to as "patients") are vertebrate subjects, more preferably mammalian subjects and more preferably human subjects. For example, in various embodiments, the compositions of the present invention are used to form self-assembled structures at sites of atherosclerotic plaque, at aneurysmal sites, at myocardial infarcts, at infectious sites, at sites of vascular damage, and so forth.
[0023] As is typical for injectable compositions, the compositions of the present invention can include one or more pharmaceutically acceptable excipients or vehicles such as water, saline, glycerol, polyethylene-glycol, hyaluronic acid, ethanol, etc.
Additionally, various auxiliary substances, such as wetting or emulsifying agents, biological buffering substances, and the like, may be present in such vehicles. A
biological buffer can be virtually any solution which is pharmacologically acceptable and which provides the formulation with the desired pH, i.e., a pH in the physiological range.
Examples of buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, and the like.
[0024] As noted above, the self-assembling nanoparticles within the coinpositions of the present invention have nanoparticle portions with attached ligands, including tissue binding and/or interparticle binding ligands, each of which will be discussed below.
[0025] The nanoparticle portions for use in the compositions of the present invention include organic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% organic molecules) such as polymeric nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% polymer molecules), and inorganic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% inorganic molecules or atoms) such as metallic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% metal atoms) and non-metallic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% non-metallic atoms).
[0026] The nanoparticle portions of the present invention can have essentially any shape and include spheres, flat or bent plates, and linear or bent elongate particles which can be any cross section including circular, annular, polygonal, irregular, and so forth (e.g., elongated cylinders, tubes, columnar shapes with polygonal cross-sections, ribbon-shaped particles, etc.), as well as other regular or irregular geometries. The dimensions of the nanoparticles can vary widely, with largest dimensions (e.g., the diameter for a sphere, the width for a plate, the length for a rod, etc.) ranging anywhere from 1 to 1,000 nm, and smallest dimensions (e.g., the diameter of a rod, the thickness of a plate, etc.) ranging anywhere from 0.1 to 100 nm.
[0027] Polymers from which the nanoparticle portions can be formed include polymers which are natural and synthetic, biodegradable or non-biodegradable, homopolymeric or copolymeric, thermoplastic or non-thermoplastic, and so forth. Suitable polymers for forming the nanoparticle portions can be selected, for example, from the following:
polycarboxylic acid polymers and copolymers including polyacrylic acids;
acetal polymers and copolymers; acrylate and methacrylate polymers and copolymers (e.g., n-butyl methacrylate); cellulosic polymers and copolymers, including cellulose acetates, cellulose nitrates, cellulose propionates, cellulose acetate butyrates, cellophanes, rayons, rayon triacetates, and cellulose ethers such as carboxymethyl celluloses and hydoxyalkyl celluloses; polyoxymethylene polymers and copolymers; polyimide polymers and copolymers such as polyether block imides, polyamidimides, polyesterimides, and polyetherimides; polysulfone polymers and copolymers including polyarylsulfones and polyethersulfones; polyamide polymers and copolymers including nylon 6,6, nylon 12, polycaprolactams and polyacrylamides; resins including alkyd resins, phenolic resins, urea resins, melamine resins, epoxy resins, allyl resins and epoxide resins;
polycarbonates; polyacrylonitriles; polyvinylpyrrolidones (cross-linked and otherwise);
polymers and copolymers of vinyl monomers including polyvinyl alcohols, polyvinyl halides such as polyvinyl chlorides, ethylene-vinylacetate copolymers (EVA), polyvinylidene chlorides, polyvinyl ethers such as polyvinyl methyl ethers, polystyrenes, styrene-maleic anhydride copolymers, styrene-butadiene copolymers, styrene-ethylene-butylene copolymers (e.g., a polystyrene-polyethylene/butylene-polystyrene (SEBS) copolymer, available as Kraton G series polymers), styrene-isoprene copolymers (e.g., polystyrene-polyisoprene-polystyrene), acrylonitrile-styrene copolymers, acrylonitrile-butadiene-styrene copolymers, styrene-butadiene copolymers and styrene-isobutylene copolymers (e.g., polyisobutylene-polystyrene block copolymers such as SIBS), polyvinyl ketones, polyvinylcarbazoles, and polyvinyl esters such as polyvinyl acetates;
polybenzimidazoles; ionomers; polyalkyl oxide polymers and copolymers including polyethylene oxides (PEO); glycosaminoglycans; polyesters including polyethylene terephthalates and aliphatic polyesters such as polymers and copolymers of lactide (which includes lactic acid as well as d-,1- and meso lactide), epsilon-caprolactone, glycolide (including glycolic acid), hydroxybutyrate, hydroxyvalerate, para-dioxanone, trimethylene carbonate (and its alkyl derivatives), 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, and 6,6-dimethyl-1,4-dioxan-2-one (a copolymer of polylactic acid and polycaprolactone is one specific example); polyether polymers and copolymers including polyarylethers such as polyphenylene ethers, polyether ketones, polyether ether ketones;
polyphenylene sulfides; polyisocyanates; polyolefin polymers and copolymers, including polyalkylenes such as polypropylenes, polyethylenes (low and high density, low and high molecular weight), polybutylenes (such as polybut- 1 -ene and polyisobutylene), poly-4-methyl-pen-l-enes, ethylene-alpha-olefin copolymers, ethylene-methyl methacrylate copolymers and ethylene-vinyl acetate copolymers; polyolefin elastomers (e.g., santoprene), ethylene propylene diene monomer (EPDM) rubbers, fluorinated polymers and copolymers, including polytetrafluoroethylenes (PTFE), poly(tetrafluoroethylene-co-hexafluoropropene) (FEP), modified ethylene-tetrafluoroethylene copolymers (ETFE), and polyvinylidene fluorides (PVDF); silicone polymers and copolymers;
polyurethanes;
p-xylylene polymers; polyiminocarbonates; copoly(ether-esters)such as polyethylene oxide-polylactic acid copolymers; polyphosphazines; polyalkylene oxalates;
polyoxaamides and polyoxaesters (including those containing amines and/or amido groups); polyorthoesters; biopolymers, such as polypeptides, proteins, polysaccharides and fatty acids (and esters thereof), including fibrin, fibrinogen, collagen, elastin, chitosan, gelatin, starch, glycosaminoglycans such as hyaluronic acid; as well as blends and further copolymers of the above.
[0028] Suitable metals from which nanoparticle portions can be formed can be selected include, for example, the following: substantially pure metals, such as silver, gold, platinum, palladium, iridium, osmium, rhodium, titanium, tungsten, and ruthenium, as well as metal alloys such as cobalt-chromium alloys, nickel-titanium alloys (e.g., nitinol), iron-chromium alloys (e.g., stainless steels, which contain 'at least 50% iron and at least 11.5% chromium), cobalt-chromium-iron alloys (e.g., elgiloy alloys), and nickel-chromium alloys (e.g., inconel alloys), among others.
[0029] Suitable non-metallic inorganic materials from which the nanoparticle portions can be formed can be selected include, for example, the following: calcium phosphate ceramics (e.g., hydroxyapatite); calcium-phosphate glasses, sometimes referred to as glass ceramics (e.g., bioglass); metal oxides, including non-transition metal oxides (e.g., oxides of metals from groups 13, 14 and 15 of the periodic table, including, for example, aluminum oxide) and transition metal oxides (e.g., oxides of metals from groups 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of the periodic table, including, for example, oxides of titanium, zirconium, hafnium, tantalum, molybdenum, tungsten, rhenium, iridium, and so forth);
carbon based materials such as pure and doped carbon (e.g., fullerenes, carbon nanofibers, single-wall, so-called "few-wall" and multi-wall carbon nanotubes), silicon carbides and carbon nitrides; silica (see Lu Y et al,., "Aerosol-assisted self-assembly of mesostructured spherical nanoparticles," Nature 398, 223-226, 18 March 1999);
synthetic or natural silicates including aluminum silicate, monomeric silicates such as polyhedral oligomeric silsequioxanes (POSS), including various functionalized POSS and polymerized POSS, and phyllosilicates including clays and micas (which may optionally be intercalated and/or exfoliated) such as montmorillonite, hectorite, hydrotalcite, vermiculite and laponite.
[0030] In some embodiments, nanoparticle portions are delivered in a physical configuration that differs from their ultimate physical configuration in vivo.
For example, in some embodiments, the nanoparticle portions are formed using shape memory materials, such as shape memory metals or shape memory polymers. Shape-memory materials have the ability to memorize a shape. Exposure to a suitable stimulus, such as heat, causes a transition of the materials from a temporary shape to their memorized shape. For example, materials can be selected that go from a less compact configuration (e.g., a linear configuration, such as a straight or flat configuration) to a more compact configuration (e.g., a non-linear or non-planar configuration, such as a coiled or otherwise bent configuration), or vice versa.
[0031] For instance, nickel-titanium films can be deposited using techniques, such as vacuum thermal evaporation, electroplating or sputtering. For this purpose, a substrate is selected which may be, for example, completely etched or dissolved at a later point in the process (e.g., a substrate formed from silicon or from a salt such as NaCl, KCI, or NaF2), or which may be formed of a material that is not ultimately etched (e.g., silicon with a polymer coating such as a polyimide film to produce a smooth, regular surface), but over which is provided a layer that is etched, for example, chromium or another material (e.g., aluminum or copper) having a highly specific etch rate relative to the nickel-titanium alloy so that the sacrificial layer may be removed without significantly etching the nickel-titanium alloy thin film. The sacrificial layer may be formed by conventional thin-film deposition techniques, such as vacuum thermal evaporation, electroplating or sputtering, to form a sacrificial layer preferably less than 1 micron in thickness. An etchant such as potassium hydroxide may be used for selectively etching aluminum, nitric acid may be used for selectively etching copper, and an etching solution containing ceric ammonium nitrate, nitric acid, and water (Chrome Etch from Arch Chemicals Inc.) may be used for selectively etching chromium. Nickel-titanium shape-memory alloy can then be sputter deposited, for example, using a sputter target composed of a nickel-titanium alloy (e.g., containing about 50 atomic percent titanium, 50 atomic percent nickel) The alloy composition may be enriched in nickel (e.g., by as much as 1-2 percent) to adjust the transition temperature as needed. The target is sputtered in a high-vacuum sputtering apparatus. When a desired film thickness is reached, the sputter deposition step is terminated. Further information on nickel-titanium film formation can be found in U.S.
Patent Application No. 2003/0127318 to Johnson et al., which is hereby incorporated by reference in its entirety.
[0032] After sputtering is completed, distinct nickel-titanium alloy nanoparticles are formed on the substrate using metal masking and etching techniques such as those that are well known in the semiconductor industry. For example, a mask can be formed lithographically, followed by selective etching of certain areas of the nickel-titanium alloy through apertures in the mask (e.g., using a plasma etching process).
Lithographic techniques have advanced rapidly. For example, the use of light coupling masks (LCM) for optical lithography has produced 80 nm features on a 200 nm pitch, using 248 nm illumination. Even smaller structures may be produced, for example, by resorting to extreme ultraviolet lithography, X-ray lithography and/or electron beam lithography. The mask can be removed after etching to expose the now discrete nanoparticles.
[0033] Subsequently, the film is annealed under heating/cooling conditions to achieve desired shape-memory alloy properties in the device. The annealing step may be, for example, by thermal heating or by exposure to an infrared heater in vacuum.
Following annealing, the particles are released, for example, by exposure to a dissolving/etching solution as discussed above. For further information on annealing and film release, see U.S. Patent Application No. 2003/0127318.
[0034] When the nanoparticles are deformed and subsequently heated above the transition temperature, they revert to their original as-deposited shape, which may be example, a planar (i.e., flat) configuration or to a non-planar (e.g., bent) configuration, depending on the shape of the substrate on which they are deposited. For examples, in the former case, particles that have been bent at lower temperature will revert to a flattened configuration upon heating. Conversely, in the latter case, particles that are flattened at a lower temperature will bend upon heating. Nanoparticles may be bent or flatted at low temperature, for example, by depositing the film on a piezoelectric or electroactive polymer substrate and bent on demand. In addition, mechanical formation (e.g., pressing) is used on still other embodiments.
[0035] As an alternative to the above, a nickel-titanium alloy film having a graded composition can be formed, for example, as described in U.S. Patent Application No.
20030162048 to Ho et al. By gradual heating of the target during deposition of the thin film, a compositionally graded film is produced. Because the shape memory transition temperature in nickel-titanium alloy is very sensitive to composition, a bimorphic film of austenite and martensite is produced by this technique that exhibits a two-way shape memory effect without the need for further heat treatment. Hence, such films take on a first shape when heated, while reverting to a second shape when cooled. After forming the film, it is then patterned into nanoparticles and released as discussed above.
Assuming that a flat substrate is used, the film curls when heated and returns to a flat configuration when cooled.
[0036] Another way of achieving a two-way shape memory effect is to introduce a biasing force by tailoring precipitates in the film such that there are compressive and tensile stresses on opposite sides of the film. See K. Kuribayashi, et al., "Micron sized arm using reversible TiNi alloy tin film actuators," Mat. Res. Soc. Symp.
Pro., vol.276, p.167,1992. This film curls when in the martensitic phase and when heated to the austenite phase it is flattened because the higher modulus overcomes the residual stresses.
[00371 Other materials are available, besides metals, which exhibit a shape memory effect, including shape memory polymers. For example, U.S. Patent Application No.
2003/0055198 to Langer et al. describes various polymers having a shape memory effect.
[0038] Shape memory polymers frequently contain phase separated block co-polymers that have a hard segment and a soft segment. The melting point or glass transition temperature (TtraõS) of the soft segment is substantially less than the melting point or glass transition temperature (Tt.S) of the hard segment. When the shape memory polymer is heated above the Tuaõs of the hard segment, the material can be shaped. This first shape can be memorized by cooling the shape memory polymer below the Tt.s of the hard segment. When the material is in a second shape at a temperature that is lower than the Ttrans of the soft segment, the first shape is recovered by heating the material above the Ttraas of the soft segment but below the Tt,a,s of the hard segment. Examples of polymers used to prepare hard and soft segments of shape memory polymers vary widely and include various polyethers, polyacrylates, polyamides, polysiloxanes, polyurethanes, polyether amides, polyurethane/ureas, polyether esters, and urethane/butadiene copolymers.
[0039] U.S. Patent Application No. 2003/0055198 also describes a wide range of shape memory polymer compositions, which include a hard segment and at least one soft segment, and which can hold more than one shape in memory, if desired. At least one of the hard or soft segments can contain a crosslinkable group, and the segments can be linked by formation of an interpenetrating network or a semi-interpenetrating network, or by physical interactions of the blocks. Objects can be formed into a given shape at a temperature above the Tt~aõs of the hard segment, and cooled to a temperature below the Tt,aõ5 of the soft segment. If the object is subsequently formed into a second shape, the object can return to its original shape by heating the object above the Ttraõs of the soft segment and below the TtraõS of the hard segment. The compositions can also include two soft segments which are linked via functional groups that are cleaved in response to application of light, electric field, magnetic field or ultrasound. The cleavage of these groups causes the object to return to its original shape. The hard and soft segments can be selected, for example, from polyhydroxy acids, polyorthoesters, polyether esters such as oligo(p-dioxanone), polyesters, polyamides, polyesteramides, polydepsidpetides, aliphatic polyurethanes, polysaccharides, polyhydroxyalkanoates, and copolymers thereof.
[0040] Once an appropriate polymer is selected, a layer of it is deposited of a substrate, for example, using thermoplastic or solvent casting techniques. As with metals, techniques for selectively masking and etching polymeric layers are well known in the semiconductor industry, where polymers are often employed, for example, due to their low dielectic constants. Once formed on the surface, the nanoparticles can be released by substrate/sacrificial layer etching as described above. As also described above, these nanoparticles can be processed to have a shape memory before being released, with the memorized shape depending on the shape of the substrate. Similar to the above, the nanoparticles are bent or flattened from their memorized shape on demand in some embodiments by depositing the polymer film on a piezoelectric or electroactive polymer or shape memory metal substrate. Moreover, residual stresses during formation may also be sufficient to bend or flatten the nanoparticles, thereby avoiding the need for actual deformation. In addition, mechanical formation (e.g., pressing) is used on still other embodiments.
[0041] In accordance with another specific embodiment of the invention, heat shrinkable nanoparticles are employed other than shape memory materials. For example, collagen particles having diameters ranging from about 3 to 40 microns, and with a minimum diameter of about 0.1 micron, have been prepared by emulsifying and cross-linking native collagen. Rossler B, et al., "Collagen microparticles: preparation and properties," J.
Microencapsul.; 1995 Jan-Feb; 12(1): 49-57. The particle size is primarily controlled by the molecular weight of the collagen that was used, with an increase in denaturation of the collagen resulting in smaller particle sizes. Id. It is well known that collagen shrinks when heated. Haines, BM, "Shrinkage temperature in collagen fibres." Leather Conservation News, 3:1-5, 1987.
[0042] Magnetostrictive particles are also known, which change their size when a magnetic field is applied.
[0043] Hence, using the above and other techniques, nanoparticles can be formed which change shape when exposed to a suitable stimulus, such as heat. Consequently, once attached to tissues within the body, these nanoparticles can be activated to change shape.
[0044] For example, certain of these materials can be activated via localized application of heat or other stimulus (e.g., via a catheter or other insertable instrument).
[0045] Alternatively, certain of these materials can be activated using ex vivo stimulation to achieve an in vivo shape change. Sources of ex vivo stimulation include, for instance, oscillating magnetic fields, electromagnetic radiation (e.g., RF and microwave radiation), ultrasound, and so forth.
[0046] For example, magnetic nanoparticles can be heated by inductive heating using an oscillating magnetic field. To the extent that the material of interest is not intrinsically magnetic, magnetic nanoparticles, such as ferrite nanoparticles, can be added as susceptor particles. Alternatively, the material can be heated in situ using focused radiofrequency radiation, microwave radiation or ultrasound.
[0047] In some embodiments, the nanoparticles of the present invention are further provided with a drug, which can be delivered in vivo after self-assembly of nanoparticles.
[0048] As opposed to particles having only tissue binding ligands, the nanoparticies described herein contain interparticle binding ligands as well, allowing them to continue with interparticle assembly beyond the point of tissue contact. Consequently, self-assembled structures are formed in accordance with the present invention, which contain enhanced quantities of drugs.
[0049] "Drugs," "therapeutic agents," "pharmaceutically active agents," and other related terms may be used interchangeably herein and include genetic and non-genetic Therapeutic agents may be used singly or in combination. Therapeutic agents may be, for example, nonionic or they may be anionic and/or cationic in nature.
[0050] Exemplary non-genetic therapeutic agents for use in connection with the present invention include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone) and tissue plasminogen activator (TPA); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel (including particulate forms thereof such as ABRAXANE albumin-bound paclitaxel nanoparticles), 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD
peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;
(f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promotors; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (1) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; (o) agents that interfere with endogenous vasoactive mechanisms; (p) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (q) cytokines; (r) hormones; (s) inhibitors of HSP 90 protein (i.e., Heat Shock Protein, which is a molecular chaperone or housekeeping protein and is needed for the stability and function of other client proteins/signal transduction proteins responsible for growth and survival of cells) including geldanamycin;
(t) beta-blockers, (u) bARKct inhibitors, (v) phospholamban inhibitors, and (w) Serca 2 gene/protein.
[0051] Exemplary genetic therapeutic agents for use in connection with the present invention include anti-sense DNA and RNA as well as DNA coding for the various proteins (as well as the proteins themselves): (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic and other factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, endothelial mitogenic growth factors, epidermal growth factor, transforming growth factor a and (3, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ' ("TK") and other agents useful for interfering with cell proliferation. Also of interest is DNA encoding for the family of bone morphogenic proteins ("BMP's"), including BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.
[0052] Vectors for delivery of genetic therapeutic agents include viral vectors such as adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, replication competent viruses (e.g., ONYX-015) and hybrid vectors; and non-viral vectors such as artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers such as polyvinylpyrrolidone (PVP), SP 1017 (SUPRATEK), lipids such as cationic lipids, liposomes, lipoplexes, nanoparticles, or microparticles, with and without targeting sequences such as the protein transduction domain (PTD).
[0053] Numerous therapeutic agents, not necessarily exclusive of those listed above, have been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis. Such agents are useful for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/guanylate cyclase stimulants such as forskolin, as well as adenosine analogs, (d) catecholamine modulators including a-antagonists such as prazosin and bunazosine, (3-antagonists such as propranolol and a/(3-antagonists such as labetalol and carvedilol, (e) endothelin receptor antagonists, ( fl nitric oxide donors/releasing molecules including organic nitrates/nitrites such as nitroglycerin, isosorbide dinitrate and amyl nitrite, inorganic nitroso compounds such as sodium nitroprusside, sydnonimines such as molsidomine and linsidomine, nonoates such as diazenium diolates and NO
adducts of alkanediamines, S-nitroso compounds including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), as well as C-nitroso-compounds, 0-nitroso-compounds, N-nitroso-compounds and L-arginine, (g) Angiotensin Converting Enzyme (ACE) inhibitors such as cilazapril, fosinopril and enalapril, (h) ATII-receptor antagonists such as saralasin and losartin, (i) platelet adhesion inhibitors such as albumin and polyethylene oxide, (j) platelet aggregation inhibitors including cilostazole, aspirin and thienopyridine (ticlopidine, clopidogrel) and GP IIb/IIIa inhibitors such as abciximab, epitifibatide and tirofiban, (k) coagulation pathway modulators including heparinoids such as heparin, low molecular weight heparin, dextran sulfate and (3-cyclodextrin tetradecasulfate, thrombin inhibitors such as hirudin, hirulog, PPACK(D-phe-L-propyl-L-arg-chloromethylketone) and argatroban, FXa inhibitors such as antistatin and TAP (tick anticoagulant peptide), Vitamin K inhibitors such as warfarin, as well as activated protein C, (1) cyclooxygenase pathway inhibitors such as aspirin, ibuprofen, flurbiprofen, indomethacin and sulfinpyrazone, (m) natural and synthetic corticosteroids such as dexamethasone, prednisolone, methprednisolone and hydrocortisone, (n) lipoxygenase pathway inhibitors such as nordihydroguairetic acid and caffeic acid, (o) leukotriene receptor antagonists, (p) antagonists of E- and P-selectins, (q) inhibitors of VCAM-1 and ICAM-1 interactions, (r) prostaglandins and analogs thereof including prostaglandins such as PGE1 and PGI2 and prostacyclin analogs such as ciprostene, epoprostenol, carbacyclin, iloprost and beraprost, (s) macrophage activation preventers including bisphosphonates, (t) HMG-CoA
reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin and cerivastatin, (u) fish oils and omega-3-fatty acids, (v) free-radical scavengers/antioxidants such as probucol, vitamins C and E, ebselen, trans-retinoic acid and SOD mimics, (w) agents affecting various growth factors including FGF pathway agents such as bFGF antibodies and chimeric fusion proteins, PDGF receptor antagonists such as trapidil, IGF
pathway agents including somatostatin analogs such as angiopeptin and ocreotide, TGF-(3 pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF-P antibodies, EGF
pathway agents such as EGF antibodies, receptor antagonists and chimeric fusion proteins, TNF-a pathway agents such as thalidomide and analogs thereof, Thromboxane A2 (TXA2) pathway modulators such as sulotroban, vapiprost, dazoxiben and ridogrel, as well as protein tyrosine kinase inhibitors such as tyrphostin, genistein and quinoxaline derivatives, (x) MMP pathway inhibitors such as marimastat, ilomastat and metastat, (y) cell motility inhibitors such as cytochalasin B, (z) antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, which is a chlorinated purine nucleoside analog), pyrimidine analogs (e.g., cytarabine and 5-fluorouracil) and methotrexate , nitrogen mustards, alkyl sulfonates, ethylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas, cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, Epo D, paclitaxel and epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), rapamycin, cerivastatin, flavopiridol and suramin, (aa) matrix deposition/organization pathway inhibitors such as halofuginone or other quinazolinone derivatives and tranilast, (bb) endothelialization facilitators such as VEGF and RGD peptide, and (cc) blood rheology modulators such as pentoxifylline.
[0054] Numerous additional therapeutic agents useful for the practice of the present invention are also disclosed in U.S. Patent No. 5,733,925 assigned to NeoRx Corporation, the entire disclosure of which is incorporated by reference.
[0055] In some embodiments, drugs are linked to the nanoparticle portions using covalent coupling techniques such as those discussed below in conjunction with ligand coupling.
[0056] In some embodiments, drugs are provided within nanocapsules, which either correspond to the nanoparticle portion or which are coupled to the nanoparticle portion.
In this connection, polyelectrolyte nanocapsules have a number of desirable properties that make them useful for purposes of the present invention. For example, they permit the encapsulation of a wide variety of therapeutic and other agents, including small molecule pharmaceuticals, polypeptides (e.g., proteins such as enzymes), polynucleotides (e.g., DNA and RNA), and so forth. See, e.g., "Microencapsulation of Organic Solvents in Polyelectrolyte Multilayer Micrometer-sized Shells," S. Moya et al., .Iournal of Colloid and Interface Science, 216, 297-302 (1999). In addition, drugs can be loaded within these nanocapsules with high precision, for example, in multiples of 0.1 pico-gram per nanocapsule. See, e.g., "Assembly of Alternated Multivalent Ion/Polyelectrolyte Layers on Colloidal Particles," I.L. Radtchenko et al., Journal of Colloid and Interface Science, 230, 272-280 (2000).
[0057] Polyelectrolyte nanocapsules can be prepared using various known layer-by-layer techniques. Layer-by-layer techniques typically involve coating particles or droplets dispersed in aqueous media via electrostatic, self-assembly using charged polymeric (polyelectrolyte) materials. These techniques exploit the fact that the particles or droplets serving as templates for the polyelectrolyte layers each has a surface charge.
This renders the particles water dispersible and provides the charge necessary for deposition of subsequent polyelectrolyte layers. Multilayers are formed by repeated treatment with alternating oppositely charged polyelectrolytes, i.e., by alternating treatment with cationic and anionic polyelectrolytes. The polymer layers self-assemble onto the pre-charged solid/liquid particles by means of electrostatic, layer-by-layer deposition, thus forming a multilayered polymeric shell around the cores.
[0058] Many materials, such as polypeptides and polynucleotides, have an inherent surface charge that is present on particles made from the same. Other materials are uncharged. Such materials, however, can nonetheless be encapsulated by layer-by-layer techniques, for example, by providing them within particles or droplets which have a surface charge [0059] Polyelectrolytes are polymers having ionically dissociable groups, which can be a component or substituent of the polymer chain. Usually, the number of these ionically dissociable groups in the polyelectrolytes is so large that the polymers in dissociated form (also called polyions) are water-soluble. Specific examples of polycations include protamine sulfate polycations, poly(allylamine) polycations (e.g., poly(allylamine hydrochloride) (PAH)), polydiallyldimethylammonium polycations, polyethyleneimine polycations, chitosan polycations, eudragit polycations, gelatine polycations, spermidine polycations and albumin polycations. Specific examples of polyanions include poly(styrenesulfonate) polyanions (e.g., poly(sodium styrenesulfonate) (PSS)), polyacrylic acid polyanions, sodium alginate polyanions, eudragit polyanions, gelatine polyanions, hyaluronic acid polyanions, carrageenan polyanions, chondroitin sulfate polyanions, and carboxymethylcellulose polyanions.
[0060] By using polyelectrolytes that are degradable, the release of enclosed drug can be controlled via the degradation of the nanocapsule walls. Otherwise, release is typically controlled by diffusion.
[0061] The wall thickness provided by layer-by-layer techniques will frequently range, for example, from 4 to 50 nm. The size of the resulting nanocapsules can vary widely, depending upon the size of the template, and will frequently range, for example, from 50 to 1000 nanometers in largest dimension, but dimensions beyond these values may also be provided.
[0062] Techniques other than direct encapsulation are also available for encapsulating agents of interest within polyelectrolyte shells. For example, various techniques take advantage of gradients across the nanocapsule wall to effect precipitation or synthesis of a desired substance within the shell. For instance, as a general rule, large macromolecules typically cannot penetrate polyelectrolyte multilayers, while small molecules, on the other hand, can. Accordingly, the presence of macromolecules inside the nanocapsules can lead to a difference in the physico-chemical properties between the inside and the outside of the nanocapsule, for example, providing gradients in pH and/or polarity that can be used to trap materials within the nanocapsules.
[0063] Moreover, charged drugs can be substituted for one or more of the polyelectrolyte layers, thereby incorporating the drug between polyelectrolyte layers within the capsule shell.
[0064] Materials instead of, or addition to, drugs can also be encapsulated using polyelectrolyte deposition techniques. As a specific example, the encapsulation of magnetite (Fe304) nanoparticles inside poly(styrene sulfonate)/poly(allylamine hydrochloride polyelectrolyte multilayers has been reported. Micron and submicron sized nanocapsules are made by means of layer-by-layer adsorption of oppositely charged polyelectrolytes (PSS, PAH) on the surface of colloidal template particles (e.g., weakly cross-linked melamine formaldehyde particles having a precipitated PAH-citrate complex) with subsequent degradation of the template core. This leaves free PAH in the core, which creates a pH gradient across the shell. At this point, (a) negatively charged, preformed magnetic particles of sufficiently small size (e.g., Fe304 nanoparticles) can be used to impregnate the nanocapsules whereupon they are held by electrostatic interactions, or (b) magnetic material (e.g., Fe304) can be selectively synthesized inside the core based on the pH gradient and on presence of dissolved PAH in the nanocapsule.
The resulting nanocapsules are easily driven by a magnetic field. Additional information can be found, for example, in "Micron-Scale Hollow Polyelectrolyte Nanocapsules with Nanosized Magnetic Fe304 Inside," Materials Letters, D.G. Shchukin et al. (in press), the disclosure of which is hereby incorporated by reference. If desired, drugs can be incorporated into such nanocapsules along with the magnetic material.
[0065] Further information on the formation of nanocapsules having polyelectrolyte shells can be found, for example, in United States Patent Application Serial No.
10/638,739, United States Patent Application Pub. No. 2002/0187197, WO
99/47252, WO 00/03797, WO 00/77281, WO 01/51196, WO 02/09864, WO 02/09865, WO
02/17888, "Fabrication of Micro Reaction Cages with Tailored Properties," L.
Dahne et al., J. Am. Chena. Soc., 123, 5431-5436 (2001), "Lipid Coating on Polyelectrolyte Surface Modified Colloidal Particles and Polyelectrolyte Nanocapsules," Moya et al., Macrornolecules, 33, 4538-4544 (2000); "Controlled Precipitation of Dyes into Hollow Polyelectrolyte Nanocapsules," G. Sukhorukov et al., Advanced Materials, Vol.
12, No.
2, 112-115 (2000), "A Novel Method for Encapsulation of Poorly Water-soluble Drugs:
Precipitation in Polyelectrolyte Multilayer Shells," I.L. Radtchenko et al., International Jouf-nal of Pharrnaceutics, 242, 219-223 (2002), the disclosures of which are hereby incorporated by reference.
[0066] For nanoparticles containing encapsulated drugs, drug release can occur, for example, due to one or more of the following mechanisms: (a) as a result of diffusion through the encapsulation layer or layers, (b) as a result of biodegradation of the encapsulation layer(s), and (c) as a result of increased permeability or breakage of the encapsulation layer(s), for example, due to external stimulation using radiofrequency radiation, microwave radiation, oscillating magnetic fields, or ultrasound (which can assist with delivery, for example, via the generation of thermal energy or via acoustic cavitation). For example, using Magnetic Resonance Imaging (MRI) fields at diagnostic levels, researchers at the Biological Systems Office (BSO), Johnson Space Center have heated microcapsules containing ferromagnetic particles to a temperature that is sufficient to melt holes in the outer skin of the microcapsules. Similarly, ferromagnetic nanoparticles within polyelectrolyte capsules (see above) could be likewise heated to the point where they penetrate the polyelectrolyte shell, so long shell materials are chosen which have melting temperatures that are below the temperatures attained by the ferromagnetic nanoparticles during heating.
[0067] For nanoparticles having attached drugs, release can occur, for example, due to one or more of the following mechanisms: (a) as a result of biodegradation of the nanoparticles, (b) as a result of biodegradation of a coupling species between the nanoparticles and the drugs, (c) by selection of a thermosensitive coupling, which is severed by heating the particle to which it is attached or the environment that it occupies (e.g., by exposure to ultrasound, alternating magnetic fields and radio- and microwave-frequency electromagnetic fields).
[0068] Some embodiments of the invention involve nanoparticles which can be heated in vivo to produce localized cell death, for example, by exposing the assembled nanoparticles to ultrasound, alternating magnetic fields and radio- and microwave-frequency electromagnetic fields as discussed above. Mechanisms of cell death due to heating include necrotic processes and apoptotic process. Necrotic cells undergo swelling and rupture, while apoptotic cells are removed by phagocytosis because they display markers on their cell surfaces that target them for selective e.limination.
Mild hyperthermia (e.g., 43 C for 30 to 60 minutes) is known to enhance apoptosis in normal and cancerous cell populations, while higher teinperatures (e.g., higher than 56 C) trigger the necrotic process. For more information see, e.g., Andrea Jordan et al., "Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia," Journal of Magnetism and Magnetic Materials, 225 (2001) 118-126; and Kuznetsov AA et al., "'Smart' mediators for self-controlled inductive heating," European Cells and Materials, Vol. 3. Suppl. 2, 2002 (pages 75-77).
[0069] As previously noted, an important feature of the present invention is that the nanoparticles self assemble in vivo. Self assembly is directed in the present invention by providing the nanoparticles with ligands, which attach to tissue in the body or which attach to ligands on other nanoparticles.
[0070] The ligands for binding the nanoparticles of the present invention to tissue will depend upon the tissue being targeted. Tissue attachment ligands can be selected, for example, the following species (or portions thereof): ankyrins, cadherins, members of the immunoglobulin superfamily (which includes a wide array of molecules, including NCAMs, ICAMs, VCAMs, and so forth), selectins (L-, E- and P- subcalsses), proteoglycans, connexins, mucoadhesives, sialyl Lex, plant or bacterial lectins (adhesion molecules which specifically bind to sugar moieties of the epithelial cell membrane), laminins, dermatan sulphate, entactin, fibrin, fibronectin, vimentin, collagen, glycolipids, glycophorin, glycoproteins, heparan sulphate, heparin sulphate, hyaluronic acid, keratan sulphate, spektrin, von Willebrand factor, vinculin, vitronectin, and polypeptides and proteins containing various peptide sequences including RGD tripeptide (i.e., ArgGlyAsp, which has been identified to be responsible for some of the cell adhesion properties of fibronectin, laminin, collagen I, collagen IV, thrombospondin, and tenascin), REDV
tetrapeptide (i.e., Arg-Glu-Asp-Val ), which has been shown to support endothelial cell adhesion but not that of smooth muscle cells, fibroblasts, or platelets), and YIGSR
pentapeptide (i.e., TyrIleGlySerArg, which promotes epithelial cell attachment, but not platelet adhesion). More information on these and other peptides can be found in U.S.
Patent No. 6,156,572 and U.S. Patent Application No. 2003/0087111.
[0071] In this connection, small oligopeptides (e.g., two to 12 amino acids) are normally rapidly removed from the body, with various processes involved in their clearance. See Meijer DK, et al., "Disease-induced drug targeting using novel peptide-ligand albumins,"
JControl Release; 2001 May 14;72(1-3):157-64. However, by coupling of such peptides to nanoparticles, elimination via various pathways is expected to be reduced or prevented.
[0072] Thus, interactions between ligands and tissues are selective in the present invention, with beneficial tissue-ligand interactions including ligand-cell receptor interactions, antibody-antigen type interactions (e.g., using whole antibodies or antibody fragments), interactions between enzymes and coenzymes and inhibitors, and nucleic acid hybridization, among other interactions.
[0073] A few specific examples of tissue targeting ligands are discussed in detail below.
[0074] For example, histologic features of vulnerable plaques include a large lipid core, a thin fibrous cap, intraplaque hemorrhage, and an increased number of inflammatory cells, particular monocyte-macrophages. Plaque is composed of a core (containing, for example, lipid and cholesterol crystals, macrophages, foam cells, necrotic cell debris, plasma proteins and degenerating blood elements) that is separated from the lumen by a layer of fibrous tissue, also known as a fibrous cap (containing, for example, smooth muscle cells, macrophages, foam cells, collagen, elastin, proteoglycans and other extracellular matrix [ECM] components).
[0075] Hence, where the targeted tissue is atherosclerotic plaque, ligands can be selected based on the presence or expression of various molecular species in the ECM
components of the plaque. In particular, plaque remodelling is known to occur by matrix metalloproteinases (MMPs), specifically MMP-1, MMP-2, MMP-3 and MMP-9. See Zaltsman AB et al., "Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity," Arterioscler Thromb Vasc Biol; 1999 Jul;
19(7):1700-7.
Moreover, various tissue inhibitors of metalloproteinases (TIMPs) at known to preferentially bind to matrix metalloproteinases. For instance, TIMP-1 preferentially binds to MMP-1 and MMP-9, TIMP-2 preferentially binds to MMP-2, and TIMP-3 preferentially binds to MMP-1 and MMP-9. Id. Mutants of TIMPs have also been reported which have enhanced binding affinity to MMPs, including MMP-2 and MMP-3.
Shuo Wei et al., "Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain," J. Biol. Chem., Vol. 278, Issue 11, 9831-9834, March 14, 2003. Accordingly, in one embodiment of the invention, TIMPs , or analogs or derivatives thereof, are used for targeting plaque.
[0076] Antibodies are also available, or they can be generated using known techniques, for targeting MMPs in the fibrous cap. For example, rabbit anti-MMP-1 (which binds to MMP-1 but does not cross react with MMP family members MMP-2A, MMP-2B, and MMP-3, MMP-9), is available from Research Diagnostics Inc., Flanders NJ, USA.
Also available form Research Diagnostics Inc. are mouse anti-human MMP-3 monoclonal antibody, rabbit Anti-MMP-3 antibody, mouse anti-human MMP-9 monoclonal antibody, and rabbit anti-MMP-9 antibody. Accordingly, in another embodiment of the invention, anti-MMP antibodies, or fragments, analogs or derivatives thereof, are used for targeting plaque.
[0077] Type III collagen in the fibrous cap is another target for self-assembly, based on its exposure and the loss of the basement membrane that overlays the cap. See, e.g., Kolodgie FD et al., "Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion," Arterioscler Thromb Vasc Biol; 2002 Oct 1;
22(10):1642-8. Antibodies are also available, or can be generated, for use in forming ligands that bind to collagen III. For example, mouse collagen type III
monoclonal antibody, is available from Chemicon International, Inc, Temecula, CA, USA and rabbit collagen III antibody and mouse collagen III antibody are available from Abcam; Ltd., Cambridge, UK. Hence, in another embodiment of the invention, anti collagen type III
antibodies, or fragments, analogs or derivatives thereof, are used for targeting plaque.
[0078] Another target for self-assembly is lipoprotein (a) matrix metalloproteinase-derived F2, since this is present in regions of increased matrix metalloproteinase 2 and matrix metalloproteinase 9. See Fortunato JE et al., "Apolipoprotein (a) fragments in relation to human carotid plaque instability," J Vasc Surg; 2000 Sep;
32(3):555-63.
[0079] Apoptosis is common in advanced human atheroma and contributes to plaque instability. Annexin V (a member of the annexin family of calcium-dependent phospholipid-binding proteins) has a high affinity for exposed phosphatidylserine on apoptotic cells. See Kolodgie FD, et al., "Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque," Circulation. 2003 Dec 23;108(25):3134-9. In addition, benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone (Z-VAD-fmk), is known to be a potent inhibitor of the enzymatic cascade intimately associated with apoptosis. See Haberkorn U, et al., "Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone,"
Nucl Med Biol. 2001 Oct;28(7):793-8.
[0080] Moreover, the presence of an inflammatory stimulus increases the expression of CC (cysteine-cysteine motif) chemokine receptor (CCR)-2 on monocytes and macrophages, as well as somatostatin receptors on T lymphocytes. Monocyte chemoattractant protein (MCP)-1 binds with high affinity to CCR-2'and is thus used to detect subacute and chronic inflammatory lesions. See Blankenberg FG, et al., "Development of radiocontrast agents for vascular imaging: progress to date,"
Am J
Cardiovasc Drugs; 2002;2(6):357-65. In addition, octreotide or depreotide are used to detect activated T lymphocytes which may identify vulnerable plaque. Id. MCP-1 and fluoro-2-deoxyglucose have been shown in animal models to be effective in identifying macrophage infiltration and metabolic activity in atheromatous lesions, respectively. Id.
[0081] Furthermore, MDC, fractalkine, and TARC, which are chromosome 16q13 chemokines, are expressed in atherosclerotic lesions. Greaves DR et al., "Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions," Arterioscler Thromb Vasc Biol; 2001 Jun;21(6):923-9.
[0082] Peptides such as endothelin are also being explored as agents for collecting at unstable atherosclerotic plaque. Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q JNucl Med; 2003 Dec; 47(4):279-91.
[0083] Consequently ligands containing annexin V, Z-VAD-fmk, (MCP)-1, octreotide, depreotide, fluoro-2-deoxyglucose, MDC, fractalkine, TARC and endothelin, among others, or fragments, analogs or derivatives thereof, are used in certain embodiments of the invention for targeting plaque.
[0084] In addition to plaque, apoptosis is also associated with cancer, acute cerebral and myocardial ischemic injury and infarction, immune mediated inflammatory disease and transplant rejection. See Blankenberg FG, "Recent advances in the imaging of programmed cell death,", Curr Pharrn Des, 2004;10(13):1457-67 and Blankenberg F, et al., "Imaging cell death in vivo," Q JNucl Med; 2003 Dec;47(4):337-48. Hence, in some embodiments of the invention, ligands containing species with a high affinity for apoptotic cells, such as annexin V and Z-VAD-fmk (or fragments, analogs or derivatives thereof), among others, are used for the treatment and/or diagnosis of these conditions as well.
[0085] With respect to infarcts, antimyosin Fab, a Fab monoclonal antibody fragment, is known to provide great specificity for the detection of inyocardial necrosis, irrespective of the cause of injury. Khaw BA, "The current role of infarct avid imaging,"
Senain Nucl Med; 1999 Jul;29(3):259-70. For example, five patients with a history of remote infarction and acute necrosis were reported to show antimyosin uptake only in regions concordant with the acute episodes of infarction, and radiolabeled antimyosin Fab localized in neither old infarcts nor normal, noninfarcted myocardium. Khaw BA
et al., "Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab," JNucl Med; 1987 Nov; 28(11):1671-8. Consequently ligands containing antimyosin Fab, or fragments, analogs or derivatives thereof, are used in some embodiments of the invention for targeting infarcts.
[0086] Autologous leukocytes concentrate at inflammatory and infectious sites, as do cytokines (e.g., IL-1, IL-2) and chemokines (e.g., IL-8, PF-4, MCP-1, NAP-2), complement factors (e.g., C5a and C5adR), chemotactic peptides (e.g., fMLF), other chemotactic factors (e.g., LTB4), as well as antagonists to the tuftsin receptor. van Eerd JE, et al., "Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation," Q JNucl Med; 2003 Dec; 47(4):246-55 and Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q
JNucl Med; 2003 Dec; 47(4):279-91. Hence, ligands containing these species, or fragments, analogs or derivatives thereof, are used in some embodiments of the invention for targeting inflammatory and infectious sites.
[0087] Expression of alpha(v)beta(3) integrin is increased in activated endothelial cells and vascular smooth muscle cells after vascular injury, whereas alpha(v)beta(3) integrin is minimally expressed on smooth muscle cells and is not expressed on quiescent epithelial cells. See Blankenberg FG, et al., "Development of radiocontrast agents for vascular imaging: progress to date," Ana JCardiovasc Drugs; 2002;2(6):357-65.
Moreover, it is reported that radiolabeled high-affmity peptides can be used to target the alpha(v)beta(3) integrin and visualize areas of vascular damage. Id. Hence, ligands containing this peptide or fragments, analogs or derivatives thereof, are used in accordance with some embodiments of the invention for targeting vascular damage.
[0088] In vascular damage, sub-endothelial regions are exposed, such as the basal lamina/basement membrane (which is a network of specialized ECM proteins, including type IV collagen, fibronectin, laminin, heparan sulfate proteoglycan, and nidogen which is a sulphated glycoprotein), and for larger vessels, there is a tunica media (which is composed of smooth muscle cells within a matrix of elastin, type I, III and V
collagen, proteogyycan, and so forth). Hence, ligands for targeting vascular damage also include various integrins which bind to theses species. Integrins recognize a wide variety of extracellular matrix components and cell-surface receptors, including collagen, fibronectin, vitronectin, laminin, fibrinogen, and adhesion molecules including intracellular adhesion molecules (ICAMS) and vascular adhesion molecules (VCAMS).
Members of the integrin family of cell-surface receptors are expressed on virtually all mammalian cells and mediate adhesion of cells to one another and to the extracellular matrix. Additional information can be found, for example, in U.S. Patent Appln. No.
2002/0058336 and U.S. Pat. Appln. No. 2003/0007969, the disclosures of which are hereby incorporated by reference.
[0089] For thromboembolic disease, peptides which bind to various components of thrombi are known, including peptide analogs of fibrin or fragments of fibronectin which have a distinct binding domain for fibrin, linear and cyclic peptide antagonists of the glycoprotein IIb/IIIa receptor on platelets, naturally occurring antagonists of this receptor which are found in venoms, analogues of laminin and thrombospondin which bind to other receptors on platelets, and peptides which target thrombin that which is sequestered within a fibrin clot. Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q JNucl Med; 2003 Dec; 47(4):279-91. In certain of these embodiments, the nanoparticles are provided with agents to help resolve and heal the thrombus, such as plasmin, Tissue Plasminogen Activator (TPA), growth factors and/or cell adhesion proteins, such as fibronectin, RGD peptides, etc.
[0090] Nanoparticles in accordance with the present invention are also provide,d with ligands for interparticle binding. As with ligands for tissue binding, interactions between the interparticle binding ligands are selective and include such beneficial interactions as ligand-receptor type interactions, antibody-antigen type interactions, nucleic acid interactions, and cell receptive mimetic binding, among others. A specific example of an interparticle ligand binding pair is the combination of a synthetic peptide sequence (preferable having no in vivo counterpart) and an antibody (or antibody fragment) for the same.
[0091] Once a ligand is selected, it must be associated with a nanoparticle portion, for example, those described above. In this regard, recent years have seen an enormous increase in the development of techniques for coupling polypeptides, polysaccharides, polynucleotides, and other biopolymers as well and small molecules to solid supports.
For example, coupling techniques are widely practiced for use in diagnostic applications, for instance, affinity chromatography.
[0092] In general, the immobilization technique selected will depend upon the chemical characteristics of the ligand (e.g., whether it is a polypeptide, polysaccharide, polynucleotide, small molecule substance, etc.) and the nanoparticle (e.g., whether it is organic or inorganic, metallic or non-metallic). Obviously, the technique should not destroy the binding ability of the ligand.
[0093] Depending on the available reactive groups within the selected ligand, several well known coupling chemistries are readily available for ligand immobilization, including those based on various condensation, addition, and substitution reactions. For example, amine, thiol and aldehyde coupling chemistries are well known in the coupling art. Most macromolecules contain amine groups, which can be used in amine coupling.
The choice of thiol coupling depends on the availability of thiol groups on the ligand.
However, it is relatively easy to provide a given ligand with thiol groups, if necessary.
Thiol chemistry generally considered to be more robust than the amine chemistry, so the coupling conditions are less critical. The choice of aldehyde coupling is made, for instance, with polysaccharides and glycoconjugates. With respect to streptavidin-biotin coupling, nucleic acids, polysaccharides and glycoconjugates are relatively easy biotinylated using a variety of reagents and functional groups.
[0094] With respect to the nanoparticle portions, those that are polymeric in nature frequently have organic functional groups, which can directly participate, or can be readily modified to participate, in coupling chemistries known in the art for attaching ligands, including those discussed above.
[0095] Where the nanoparticles are metallic or ceramic in nature, the surfaces are typically derivatized prior to coupling. For example, using techniques such as those described in U.S. Serial No. 10/830,772, ligands may be covalently coupled to a nanoparticle surface by a method that comprises: (a) halogenating the surface;
and (b) reacting the halogenated surface with a reactive molecule that is covalently reactive with the chlorinated surface region. For example, the surface region may be halogenated by exposing the exposing the surface region to a reactive chloride, for example, a reactive chloride selected from the following: SiC14 (silicon tetrachloride), TiC14 (titanium tetrachloride), GeC14 (germanium tetrachloride), SnCI~ (tin tetrachloride), (vanadium tetrachloride), MoCl5 (molybdenum pentachloride), WCl6 (tungsten hexachloride), BC13 (boron trichloride), and PCl5 (phosphorus pentachloride).
According to a specific example, a surface region (e.g., a metal or a ceramic surface region with available hydroxide groups) is reacted with silicon tetrachloride as a halogenating agent (in this instance, a chlorosilanization agent). This reaction scheme can be represented, for example, as follows:
M-OH + SiC1~--> M-O-SiC13 + HCI, where M corresponds to the metal or ceramic surface. Once they are produced on the surface, the chorosilane groups are then exposed to a molecule that is reactive with the same (e.g., species comprising hydroxyl groups), thereby forming a covalently coupled molecular species.
[0096] The above scheme can be conducted on a wide variety of surfaces, including various metallic and ceramic surfaces, so long as surface hydroxyl groups are available for reaction. This scheme can also be conducted on various metals which form native oxide layers. In this regard, controlled native oxide layers can be formed on most metals used today in medical devices. This technology is well known. The above reaction scheme can also be conducted on surface regions which have been pretreated to establish hydroxyl groups thereon. For example, in some embodiments, a surface region, for example, a polymeric surface region, is pretreated by subjecting it to a glow discharge step. The resulting surface region, which is hydroxylated during the glow discharge step, is then available for reaction in accordance with the above scheme.
[0097] Ligand attachment need not be covalent. For example, it is known from Michel R., et al., "Self-organized molecular assembly: patterning of surfaces at the micro- and nano-scale for biological applications," Langmuir, 2002, 18, 3281-3287, that alkane phosphates from aqueous solution will adsorb onto certain metal oxides, such as titanium or niobium oxide. Due to the presence of titanium oxide on nickel-titanium alloy surfaces, dodecylphosphate (DDP) is expected to be readily adsorbed by self-assembly from aqueous solutions of its ammonium salt, rendering the titanium oxide surface hydrophobic and hence protein-adsorbing. (In alternative embodiments, a thin layer of pure titanium oxide is formed at the nanoparticle surface.) Subsequently, polypeptide containing molecules, including proteins, are adsorbed to the surface.
[0098] If desired, ligands can be coupled to only a portion of the nanoparticle surface.
For example, lithographic masking techniques can be used to prevent contact with certain portions of the nanoparticles. As another exainple, see also, for example, A K
Salem et al. "Multifunctional nanorods for gene delivery," Nature Materials, Vol. 2, 2003, pp 668-671, which describes a non-viral gene-delivery system based on multisegment bimetallic nanorods (Au/Ni) that can simultaneously bind compacted DNA
plasmids and targeting ligands in a spatially defined manner.
[0099] Using the above and other techniques, a wide variety of ligands can be adsorbed or covalently coupled to a wide range of nanoparticle potions. For more information on ligand coupling, see, for example, Mohammed Aslam PhD and Alastair H. Dent, Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences, Nature Publishing Group, 1998; Yuri Lvov et al., Protein Architecture: Interfacing Molecular Assemblies and Immobilization Biotechnology, Marcel Dekker, 1999; and Shtilman, MI, Inamobilization on Poly zers, VSP International Science Publishers, 1993; the disclosures of which are incorporated by reference.
[0100] In many embodiments of the invention, it is desirable to non-invasively image the nanoparticles once they are assembled in vivo. Among currently available non-invasive imaging techniques are included magnetic resonance imaging (MRI), x-ray fluoroscopy and scintigraphic imaging, among others.
[0101] Magnetic resonance imaging (MRI) produces images by differentiating detectable magnetic species in the portion of the body being imaged. For contrast-enhanced MRI, it is desirable that the contrast agent have a large magnetic moment, with a relatively long electronic relaxation time. Based upon these criteria, contrast agents such as Gd(III), Mn(II) and Fe(III) have been employed. Gadolinium(III) has the largest magnetic moment among these three and is, therefore, a widely-used paramagnetic species to enhance contrast in MRI. Chelates of paramagnetic ions such as Gd-DTPA
(gadolinium ion chelated with the ligand diethylenetriaminepentaacetic acid) have also been employed as MRI contrast agents. In accordance with certain embodiments of the invention, paramagnetic ion chelates can be attached to selected nanoparticle portions using coupling techniques such as those described above.
[0102] As seen above, many species useful as tissue targeting ligands are currently available in radiolabeled form, allowing them to be imaged. Alternatively, techniques are well-known for providing ligands with radiolabeled atoms.
[0103] With respect to x-ray based fluoroscopy, some nanoparticles such as metallic nanoparticles are inherently more absorptive of x-rays than surrounding tissue.
Alternatively, the nanoparticles of the present invention can be provided with contrast agents, in certain embodiments, such as metals (e.g., tungsten, platinum, tantalum, iridium, gold, or other dense metal), metal compounds (e.g., barium sulfate, bismuth subcarbonate, bismuth trioxide, bismuth oxychloride, etc.) or iodinated compounds (e.g., iopamidol, iothalamate sodium, iodomide sodium).
[0104] Ultrasound uses high frequency sound waves to create an image of living tissue.
A sound signal is sent out, and the reflected ultrasonic energy, or "echoes,"
used to create the image. Ultrasound imaging contrast agents are materials that enhance the image produced by ultrasound equipment. Ultrasonic imaging contrast agents introduced into the compositions of the present invention can be, for example, echogenic (i.e., materials that result in an increase in the reflected ultrasonic energy) or echolucent (i.e., materials that result in a decrease in the reflected ultrasonic energy). Suitable ultrasonic imaging contrast agents for use in connection with the present invention include solid particles ranging from about 0.01 to 50 microns in largest dimension (e.g., the nanoparticles of the present invention may provide sufficient contrast in some instances). In other embodiments, nanobubbles (e.g., air filled nanocapsules) are used.
[0105] Hence, using the above and other techniques known to those of ordinary skill in the art, nanoparticles can be fabricated and subsequently injected into the vasculature where they attach to diseased or abnormal structures that have an identifiable marker, which may appear, for example, on the endothelium, on exposed basement membrane, on exposed extracellular matrix, and so forth. Further particles then self-assemble into a structure over the particles that initially attach to the tissue. The shape of the endovascular structure assembled will depend, for example, on the shape of the particles, the locations of the ligands, and so forth.
[0106] In some embodiments, the self-assembled structures act as stabilizing or isolating structures over diseased or aberrant tissue. For example, in some embodiments, vulnerable plaque (i.e., plaque at risk for rupture) is stabilized by the self-assembly of what effectively amounts to a patch over the plaque. Additionally, if the nanoparticles have the property that they can partition into the plaque (e.g. because they have lipophilic character that carbon nanotubes, among other particles, may possess) they may self assemble in the plaque, which may, for example, allow the assembly to be better retained, stabilize the plaque by the presence of a large structure, and/or release a variety of therapeutic agents (e.g., anti-inflammatory agents to mitigate the processes that cause the plaque to become unstable, agents to enhance healing of the plaque, agents and polymeric precursors that can gel the components of the plaque for stabilization, for instance, by crosslinking of the polymeric precursors upon release, and so forth).
Furthermore, the self assembled structure may be used as a diagnostic to locate the position of vulnerable plaques. Depending on the nature of the nanoparticles and their components, they could be visible by MRI (e.g., by using paramagnetic particles) or by catheters with spectroscopic (e.g. near infrared) detectors. For an example of the latter technique, see, e.g., PW Barone, et al. "Near-infrared optical sensors based on single-walled carbon nanotubes," Nature Materials 4 (2005) 86-92.
[0107] In some embodiments, the self-assembled structures perform a mechanical function. For instance, the structures can contract and/or expand upon activation (e.g., by exploiting shape memory or other shape-change properties of the individual particles).
Triggers for activating the shape change properties of the material include ultrasound, radiofrequency radiation, microwave radiation, or oscillating magnetic fields as discussed above. Further, a molecular aggregate with an interparticle binding ligand and a further ligand may be used to cause a conformation change when an injected agent or an agent that circulates in blood binds to this further ligand. For example, various molecules are known which change in conformation upon binding to other agents. Molecules are also known which change in conformation upon exposure to energy, which causes partial or full denaturation.
[0108] Using such techniques, in the case where a structure is self-assembled over obstructing plaque or restenotic structures, the structure is then expanded to increase the vessel diameter by activating the shape memory property of the self-assembled particles.
In this instance, the self-assembled structure is acting as an expanded stent segment. In one specific embodiment, a U-shaped shape memory rod is employed as the nanoparticle portion and ligands are provided at the ends of the U. These particles then undergo shape change and open up when triggered (e.g., by heating).
[0109] This shape change can also be used to impose a force for shrinking damaged and dilated tissue. A specific example of a beneficial shrinking structure is the case where an adherent structure is self-assembled over scarred heart muscle (e.g. from an old infarct), and then activated to contract (e.g., linear shape memory rods are employed which become U-shaped upon triggering). This contraction reshapes the heart, reducing the ventricular volume, increasing ejection fraction, and leading to positive remodelling of the heart. The reduced volume increases the force of heart contraction and ejection fraction consistent with Starling's law of the force of heart contraction.
This concept is practiced on gross scale by surgical interventions by removing the heart muscle, by ventricular reduction using the Battista or Dorr procedures, or by shrinking the scarred tissue and patching using processes such as those available from Hearten Medical, Irvine, CA, USA.
[0110] Self assembled structures can also be triggered, using techniques such as those discussed above, to release drugs or other beneficial agents that are contained in or attached to the nanoparticles. For example, these agents can be antirestenosis agents in order to treat plaque. As another example, these agents can correspond to components of single- or multi-component adhesives or glues (e.g., fibrinogen, thrombin, cyanoacrylate adhesive, etc.) to further stabilize vulnerable plaque and for aneurysmal management. As yet another example, these agents can correspond to growth factors to repair vascular tissue or to revascularize injured and/or scarred tissue, such as heart muscle following infarct.
[0111] In further embodiments, the self-assembling compositions of the present invention are used to target diseased or infected tissue, including tissue infected with bioterror agents. Upon activation the self-assembled structures (most likely in capillary beds), a drug or other argent is released to treat the disease or infection.
[0112] As a specific example, inhalation of infectious agents into the lungs is expected to result in changes of the endothelium of the capillary beds in the lungs. These aberrant endothelium can be targeted for the formation of self-assembled structures that will release anti-infectious agents at only the local site of infection. For instance, as noted above, autologous leukocytes concentrate at inflammatory and infectious sites, as do cytokines, chemokines, complement factors, chemotactic peptides, other chemotactic factors, as well as antagonists to the tuftsin receptor. Hence, ligands for nanoparticles that are intended for delivery at sites of local infection can be selected from these species.
The above and other techniques could allow the use of relatively toxic agents, since they are only released locally at the site of infection.
[0113] Self assembled endovascular structures in accordance with the present invention can also be used as a scaffolds for tissue repair. These structures would contain ligands that bind endogenous cells or injected cells. For example, as indicated above, peptides having affinity for the alpha(v)beta(3) integrin can be used to target areas of vascular damage. Moreover, integrins can also be used to target areas of vascular damage, as they recognize a wide variety of extracellular matrix components and cell-surface receptors, as previously noted. Preferred nanoparticles for forming self assembled scaffolds for tissue repair include nanoparticles of extracellular matrix materials such as collagen (e.g., type IV collagen), glycosaminoglycans, synthetic particles providing a coating with ECM-like materials to encourage healing, and so forth. The self assembled nanoparticles can also be provided with drugs or other agents which are released to attract and/or promote growth of the desired endogenous cell type.
[0114] Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.
and Wang et al. below). Other examples are linkages between groups that pair to one another via multiple hydrogen bonds. Several examples of such molecules are described in Sherrington DC and Taskinen KA, "Self-assembly in synthetic macromolecular systems via multiple hydrogen bonding interactions," Clzern. Soc. Rev., 2001, 30 (2), 83-93, and include the familiar hydrogen bonding between thymine/uracil and adenine and between cytosine and guanine, as well as higher order bonding such as bonding via four hydrogen bonds using uredopyrimidinone residues. (Note that uredopyrimidinone residues bind to one another and thus represent ligands that are the same and yet bind to one another. In this regard, such ligands are also used for interparticle binding in certain embodiments of the invention.) [00151 In other embodiments, one or both of the interparticle binding ligands are embedded within a hydrogel polymer. Upon a triggering event, which makes the hydrogel polymer go from a more hydrophobic to a more hydrophilic state (which is also accompanied by swelling of the hydrogel) or which makes the hydrogel polymer go from a more hydrophilic state to a more hydrophobic state, the binding ligand may be expelled/released from the hydrogel into the biological milieu. For example, hydrogels are known that become more hydrophilic based on changes in pH, osmolality or temperature, upon application of an electric field, and so forth. See, e.g., Chatterjee, et al., Nanotech 2003 Vol. 1, Technical Proceedings of the 2003 Nanotechnology Conference and Trade Show, Volume 1, Chapter 7: Bio Micro Systems, "Electrically Triggered Hydrogels: Mathematical Models and Simulations," pp. 130 - 133;
Eichenbaum GM, et al. "pH and Ion-Triggered Volume Response of Anionic Hydrogel Microspheres." Macromolecules. 1.998 Ju128;31(1.5):5084-93; Chen et al., "Responsive hybrid hydrogels with volume transitions modulated by a titin immunoglobulin module."
Biocoqj. Chem. 2000 Sep-Oct;1.1.(5): 734-40; Coughlan DC, et al., "Effect of drug physicochemical properties on swelling/deswelling kinetics and pulsatile drug release from thermoresponsive poly(N-isopropylacrylamide) hydrogels." J Control Release. 2004 Jul 23;98(1):97-114; Molinaro G, et al. "Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials."
Biomaterials. 2002 Jul;23(13):2717-22. Wang C, et al. "Hybrid hydrogels cross-linked by genetically engineered coiled-coil block proteins." Bionaacrornolecules.
Fall;2(3):912-20. Hence, using the above hydrogel polymers as well as other currently available polymer matrices, ligand release may be triggered, for example, by local pH
change (e.g., by flushing the area with an acidic or basic solution via catheter) to ionize ionic groups in the polymer, by heating (e.g. by heating with MRI or flushing the area with a warm solution via catheter) to force a transformation of the polymer beyond a critical transition that allows hydration, or by hydrolysis/enzymatic cleavage to expose 1lydrophilic groups in the polymer. In addition to (or as an alternative to) ligand coverage and exposure, such triggerable hydrogels may also be used to retain and release drugs.
[0016] Activation of the ligand via conformation changes may also be employed, e.g., by denaturation, pH change, temperature change, and so forth.
[0017] In certain embodiments, the nanoparticles (except for portions that contain binding ligands), may be provided with a passivating, non-reactive surface.
For example, a coating of polyethylene glycol or another known surface passivating polymer may be applied to prevent protein interactions, nonspecific binding and aggregation, and so forth.
[0018] In accordance with another aspect of the invention, a kit is provided which contains at least first and second nanoparticle-containing injectable compositions. The first injectable composition comprises first self-assembling nanoparticles which comprise the following: (a) a first nanoparticle portion (b) tissue binding ligands attached to the first nanoparticle portion which result in the preferential binding and accumulation of the nanoparticles at one or more target locations in the body, and (c) first interparticle binding ligands attached to the first nanoparticle portion to promote interparticle binding. The second injectable composition comprises second self-assembling nanoparticles which comprise the following: (a) a second nanoparticle portion and (b) second interparticle binding ligands attached to the second nanoparticle portion, which preferentially bind to the first interparticle binding ligands attached to the first nanoparticle portion. The second self-assembling nanoparticles may or may not contain tissue binding ligands.
Moreover, the first and second nanoparticle portions can be of the same or of different compositions.
[0019] In this aspect of the invention, injection of the first composition results in preferential binding and accumulation of the first self-assembling nanoparticles at one or more target locations in the body, thereby forming an initial base layer. Upon subsequent injection of the second composition, the interparticle binding ligands on the second nanoparticles preferentially bind to the first interparticle binding ligands of the first nanoparticles. By alternating the injection of the first and second coinpositions, nanoparticles are assembled on the tissue in a layer-by-layer fashion with lock-and-key specificity.
[0020] If desired, a third composition can then be administered which comprises third self-assembling nanoparticles which comprise the following: (a) a third nanoparticle portion and (b) third interparticle binding ligands attached to the third nanoparticle portion, which preferentially bind to the second interparticle binding ligands of second nanoparticles. Although tissue binding ligands can be attached to the third self-assembling nanoparticles, in many embodiments, the third self-assembling nanoparticles will not comprise tissue binding ligands. The nanoparticle portions of the third self-assembling nanoparticles can be the same as or different from the nanoparticle portions of the first and second self-assembling nanoparticles. Moreover, the third interparticle binding ligands can be the same as or different from the first interparticle binding ligands.
Upon injection of the third composition, the interparticle binding ligands on the third self-assembling nanoparticles bind to those on the previously attached second self-assembling nanoparticles.
[0021] Analogous to the above, by alternating the injection of the second and third compositions, nanoparticles are assembled on the tissue in a layer-by-layer fashion.
[0022] As previously indicated, the compositions of the present invention can be used to in the treatment of a variety of diseases and conditions. "Treatment" refers to the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition. Preferred subjects (also referred to as "patients") are vertebrate subjects, more preferably mammalian subjects and more preferably human subjects. For example, in various embodiments, the compositions of the present invention are used to form self-assembled structures at sites of atherosclerotic plaque, at aneurysmal sites, at myocardial infarcts, at infectious sites, at sites of vascular damage, and so forth.
[0023] As is typical for injectable compositions, the compositions of the present invention can include one or more pharmaceutically acceptable excipients or vehicles such as water, saline, glycerol, polyethylene-glycol, hyaluronic acid, ethanol, etc.
Additionally, various auxiliary substances, such as wetting or emulsifying agents, biological buffering substances, and the like, may be present in such vehicles. A
biological buffer can be virtually any solution which is pharmacologically acceptable and which provides the formulation with the desired pH, i.e., a pH in the physiological range.
Examples of buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, and the like.
[0024] As noted above, the self-assembling nanoparticles within the coinpositions of the present invention have nanoparticle portions with attached ligands, including tissue binding and/or interparticle binding ligands, each of which will be discussed below.
[0025] The nanoparticle portions for use in the compositions of the present invention include organic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% organic molecules) such as polymeric nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% polymer molecules), and inorganic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% inorganic molecules or atoms) such as metallic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% metal atoms) and non-metallic nanoparticle portions (i.e., nanoparticle portions comprising at least 50 wt% non-metallic atoms).
[0026] The nanoparticle portions of the present invention can have essentially any shape and include spheres, flat or bent plates, and linear or bent elongate particles which can be any cross section including circular, annular, polygonal, irregular, and so forth (e.g., elongated cylinders, tubes, columnar shapes with polygonal cross-sections, ribbon-shaped particles, etc.), as well as other regular or irregular geometries. The dimensions of the nanoparticles can vary widely, with largest dimensions (e.g., the diameter for a sphere, the width for a plate, the length for a rod, etc.) ranging anywhere from 1 to 1,000 nm, and smallest dimensions (e.g., the diameter of a rod, the thickness of a plate, etc.) ranging anywhere from 0.1 to 100 nm.
[0027] Polymers from which the nanoparticle portions can be formed include polymers which are natural and synthetic, biodegradable or non-biodegradable, homopolymeric or copolymeric, thermoplastic or non-thermoplastic, and so forth. Suitable polymers for forming the nanoparticle portions can be selected, for example, from the following:
polycarboxylic acid polymers and copolymers including polyacrylic acids;
acetal polymers and copolymers; acrylate and methacrylate polymers and copolymers (e.g., n-butyl methacrylate); cellulosic polymers and copolymers, including cellulose acetates, cellulose nitrates, cellulose propionates, cellulose acetate butyrates, cellophanes, rayons, rayon triacetates, and cellulose ethers such as carboxymethyl celluloses and hydoxyalkyl celluloses; polyoxymethylene polymers and copolymers; polyimide polymers and copolymers such as polyether block imides, polyamidimides, polyesterimides, and polyetherimides; polysulfone polymers and copolymers including polyarylsulfones and polyethersulfones; polyamide polymers and copolymers including nylon 6,6, nylon 12, polycaprolactams and polyacrylamides; resins including alkyd resins, phenolic resins, urea resins, melamine resins, epoxy resins, allyl resins and epoxide resins;
polycarbonates; polyacrylonitriles; polyvinylpyrrolidones (cross-linked and otherwise);
polymers and copolymers of vinyl monomers including polyvinyl alcohols, polyvinyl halides such as polyvinyl chlorides, ethylene-vinylacetate copolymers (EVA), polyvinylidene chlorides, polyvinyl ethers such as polyvinyl methyl ethers, polystyrenes, styrene-maleic anhydride copolymers, styrene-butadiene copolymers, styrene-ethylene-butylene copolymers (e.g., a polystyrene-polyethylene/butylene-polystyrene (SEBS) copolymer, available as Kraton G series polymers), styrene-isoprene copolymers (e.g., polystyrene-polyisoprene-polystyrene), acrylonitrile-styrene copolymers, acrylonitrile-butadiene-styrene copolymers, styrene-butadiene copolymers and styrene-isobutylene copolymers (e.g., polyisobutylene-polystyrene block copolymers such as SIBS), polyvinyl ketones, polyvinylcarbazoles, and polyvinyl esters such as polyvinyl acetates;
polybenzimidazoles; ionomers; polyalkyl oxide polymers and copolymers including polyethylene oxides (PEO); glycosaminoglycans; polyesters including polyethylene terephthalates and aliphatic polyesters such as polymers and copolymers of lactide (which includes lactic acid as well as d-,1- and meso lactide), epsilon-caprolactone, glycolide (including glycolic acid), hydroxybutyrate, hydroxyvalerate, para-dioxanone, trimethylene carbonate (and its alkyl derivatives), 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, and 6,6-dimethyl-1,4-dioxan-2-one (a copolymer of polylactic acid and polycaprolactone is one specific example); polyether polymers and copolymers including polyarylethers such as polyphenylene ethers, polyether ketones, polyether ether ketones;
polyphenylene sulfides; polyisocyanates; polyolefin polymers and copolymers, including polyalkylenes such as polypropylenes, polyethylenes (low and high density, low and high molecular weight), polybutylenes (such as polybut- 1 -ene and polyisobutylene), poly-4-methyl-pen-l-enes, ethylene-alpha-olefin copolymers, ethylene-methyl methacrylate copolymers and ethylene-vinyl acetate copolymers; polyolefin elastomers (e.g., santoprene), ethylene propylene diene monomer (EPDM) rubbers, fluorinated polymers and copolymers, including polytetrafluoroethylenes (PTFE), poly(tetrafluoroethylene-co-hexafluoropropene) (FEP), modified ethylene-tetrafluoroethylene copolymers (ETFE), and polyvinylidene fluorides (PVDF); silicone polymers and copolymers;
polyurethanes;
p-xylylene polymers; polyiminocarbonates; copoly(ether-esters)such as polyethylene oxide-polylactic acid copolymers; polyphosphazines; polyalkylene oxalates;
polyoxaamides and polyoxaesters (including those containing amines and/or amido groups); polyorthoesters; biopolymers, such as polypeptides, proteins, polysaccharides and fatty acids (and esters thereof), including fibrin, fibrinogen, collagen, elastin, chitosan, gelatin, starch, glycosaminoglycans such as hyaluronic acid; as well as blends and further copolymers of the above.
[0028] Suitable metals from which nanoparticle portions can be formed can be selected include, for example, the following: substantially pure metals, such as silver, gold, platinum, palladium, iridium, osmium, rhodium, titanium, tungsten, and ruthenium, as well as metal alloys such as cobalt-chromium alloys, nickel-titanium alloys (e.g., nitinol), iron-chromium alloys (e.g., stainless steels, which contain 'at least 50% iron and at least 11.5% chromium), cobalt-chromium-iron alloys (e.g., elgiloy alloys), and nickel-chromium alloys (e.g., inconel alloys), among others.
[0029] Suitable non-metallic inorganic materials from which the nanoparticle portions can be formed can be selected include, for example, the following: calcium phosphate ceramics (e.g., hydroxyapatite); calcium-phosphate glasses, sometimes referred to as glass ceramics (e.g., bioglass); metal oxides, including non-transition metal oxides (e.g., oxides of metals from groups 13, 14 and 15 of the periodic table, including, for example, aluminum oxide) and transition metal oxides (e.g., oxides of metals from groups 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of the periodic table, including, for example, oxides of titanium, zirconium, hafnium, tantalum, molybdenum, tungsten, rhenium, iridium, and so forth);
carbon based materials such as pure and doped carbon (e.g., fullerenes, carbon nanofibers, single-wall, so-called "few-wall" and multi-wall carbon nanotubes), silicon carbides and carbon nitrides; silica (see Lu Y et al,., "Aerosol-assisted self-assembly of mesostructured spherical nanoparticles," Nature 398, 223-226, 18 March 1999);
synthetic or natural silicates including aluminum silicate, monomeric silicates such as polyhedral oligomeric silsequioxanes (POSS), including various functionalized POSS and polymerized POSS, and phyllosilicates including clays and micas (which may optionally be intercalated and/or exfoliated) such as montmorillonite, hectorite, hydrotalcite, vermiculite and laponite.
[0030] In some embodiments, nanoparticle portions are delivered in a physical configuration that differs from their ultimate physical configuration in vivo.
For example, in some embodiments, the nanoparticle portions are formed using shape memory materials, such as shape memory metals or shape memory polymers. Shape-memory materials have the ability to memorize a shape. Exposure to a suitable stimulus, such as heat, causes a transition of the materials from a temporary shape to their memorized shape. For example, materials can be selected that go from a less compact configuration (e.g., a linear configuration, such as a straight or flat configuration) to a more compact configuration (e.g., a non-linear or non-planar configuration, such as a coiled or otherwise bent configuration), or vice versa.
[0031] For instance, nickel-titanium films can be deposited using techniques, such as vacuum thermal evaporation, electroplating or sputtering. For this purpose, a substrate is selected which may be, for example, completely etched or dissolved at a later point in the process (e.g., a substrate formed from silicon or from a salt such as NaCl, KCI, or NaF2), or which may be formed of a material that is not ultimately etched (e.g., silicon with a polymer coating such as a polyimide film to produce a smooth, regular surface), but over which is provided a layer that is etched, for example, chromium or another material (e.g., aluminum or copper) having a highly specific etch rate relative to the nickel-titanium alloy so that the sacrificial layer may be removed without significantly etching the nickel-titanium alloy thin film. The sacrificial layer may be formed by conventional thin-film deposition techniques, such as vacuum thermal evaporation, electroplating or sputtering, to form a sacrificial layer preferably less than 1 micron in thickness. An etchant such as potassium hydroxide may be used for selectively etching aluminum, nitric acid may be used for selectively etching copper, and an etching solution containing ceric ammonium nitrate, nitric acid, and water (Chrome Etch from Arch Chemicals Inc.) may be used for selectively etching chromium. Nickel-titanium shape-memory alloy can then be sputter deposited, for example, using a sputter target composed of a nickel-titanium alloy (e.g., containing about 50 atomic percent titanium, 50 atomic percent nickel) The alloy composition may be enriched in nickel (e.g., by as much as 1-2 percent) to adjust the transition temperature as needed. The target is sputtered in a high-vacuum sputtering apparatus. When a desired film thickness is reached, the sputter deposition step is terminated. Further information on nickel-titanium film formation can be found in U.S.
Patent Application No. 2003/0127318 to Johnson et al., which is hereby incorporated by reference in its entirety.
[0032] After sputtering is completed, distinct nickel-titanium alloy nanoparticles are formed on the substrate using metal masking and etching techniques such as those that are well known in the semiconductor industry. For example, a mask can be formed lithographically, followed by selective etching of certain areas of the nickel-titanium alloy through apertures in the mask (e.g., using a plasma etching process).
Lithographic techniques have advanced rapidly. For example, the use of light coupling masks (LCM) for optical lithography has produced 80 nm features on a 200 nm pitch, using 248 nm illumination. Even smaller structures may be produced, for example, by resorting to extreme ultraviolet lithography, X-ray lithography and/or electron beam lithography. The mask can be removed after etching to expose the now discrete nanoparticles.
[0033] Subsequently, the film is annealed under heating/cooling conditions to achieve desired shape-memory alloy properties in the device. The annealing step may be, for example, by thermal heating or by exposure to an infrared heater in vacuum.
Following annealing, the particles are released, for example, by exposure to a dissolving/etching solution as discussed above. For further information on annealing and film release, see U.S. Patent Application No. 2003/0127318.
[0034] When the nanoparticles are deformed and subsequently heated above the transition temperature, they revert to their original as-deposited shape, which may be example, a planar (i.e., flat) configuration or to a non-planar (e.g., bent) configuration, depending on the shape of the substrate on which they are deposited. For examples, in the former case, particles that have been bent at lower temperature will revert to a flattened configuration upon heating. Conversely, in the latter case, particles that are flattened at a lower temperature will bend upon heating. Nanoparticles may be bent or flatted at low temperature, for example, by depositing the film on a piezoelectric or electroactive polymer substrate and bent on demand. In addition, mechanical formation (e.g., pressing) is used on still other embodiments.
[0035] As an alternative to the above, a nickel-titanium alloy film having a graded composition can be formed, for example, as described in U.S. Patent Application No.
20030162048 to Ho et al. By gradual heating of the target during deposition of the thin film, a compositionally graded film is produced. Because the shape memory transition temperature in nickel-titanium alloy is very sensitive to composition, a bimorphic film of austenite and martensite is produced by this technique that exhibits a two-way shape memory effect without the need for further heat treatment. Hence, such films take on a first shape when heated, while reverting to a second shape when cooled. After forming the film, it is then patterned into nanoparticles and released as discussed above.
Assuming that a flat substrate is used, the film curls when heated and returns to a flat configuration when cooled.
[0036] Another way of achieving a two-way shape memory effect is to introduce a biasing force by tailoring precipitates in the film such that there are compressive and tensile stresses on opposite sides of the film. See K. Kuribayashi, et al., "Micron sized arm using reversible TiNi alloy tin film actuators," Mat. Res. Soc. Symp.
Pro., vol.276, p.167,1992. This film curls when in the martensitic phase and when heated to the austenite phase it is flattened because the higher modulus overcomes the residual stresses.
[00371 Other materials are available, besides metals, which exhibit a shape memory effect, including shape memory polymers. For example, U.S. Patent Application No.
2003/0055198 to Langer et al. describes various polymers having a shape memory effect.
[0038] Shape memory polymers frequently contain phase separated block co-polymers that have a hard segment and a soft segment. The melting point or glass transition temperature (TtraõS) of the soft segment is substantially less than the melting point or glass transition temperature (Tt.S) of the hard segment. When the shape memory polymer is heated above the Tuaõs of the hard segment, the material can be shaped. This first shape can be memorized by cooling the shape memory polymer below the Tt.s of the hard segment. When the material is in a second shape at a temperature that is lower than the Ttrans of the soft segment, the first shape is recovered by heating the material above the Ttraas of the soft segment but below the Tt,a,s of the hard segment. Examples of polymers used to prepare hard and soft segments of shape memory polymers vary widely and include various polyethers, polyacrylates, polyamides, polysiloxanes, polyurethanes, polyether amides, polyurethane/ureas, polyether esters, and urethane/butadiene copolymers.
[0039] U.S. Patent Application No. 2003/0055198 also describes a wide range of shape memory polymer compositions, which include a hard segment and at least one soft segment, and which can hold more than one shape in memory, if desired. At least one of the hard or soft segments can contain a crosslinkable group, and the segments can be linked by formation of an interpenetrating network or a semi-interpenetrating network, or by physical interactions of the blocks. Objects can be formed into a given shape at a temperature above the Tt~aõs of the hard segment, and cooled to a temperature below the Tt,aõ5 of the soft segment. If the object is subsequently formed into a second shape, the object can return to its original shape by heating the object above the Ttraõs of the soft segment and below the TtraõS of the hard segment. The compositions can also include two soft segments which are linked via functional groups that are cleaved in response to application of light, electric field, magnetic field or ultrasound. The cleavage of these groups causes the object to return to its original shape. The hard and soft segments can be selected, for example, from polyhydroxy acids, polyorthoesters, polyether esters such as oligo(p-dioxanone), polyesters, polyamides, polyesteramides, polydepsidpetides, aliphatic polyurethanes, polysaccharides, polyhydroxyalkanoates, and copolymers thereof.
[0040] Once an appropriate polymer is selected, a layer of it is deposited of a substrate, for example, using thermoplastic or solvent casting techniques. As with metals, techniques for selectively masking and etching polymeric layers are well known in the semiconductor industry, where polymers are often employed, for example, due to their low dielectic constants. Once formed on the surface, the nanoparticles can be released by substrate/sacrificial layer etching as described above. As also described above, these nanoparticles can be processed to have a shape memory before being released, with the memorized shape depending on the shape of the substrate. Similar to the above, the nanoparticles are bent or flattened from their memorized shape on demand in some embodiments by depositing the polymer film on a piezoelectric or electroactive polymer or shape memory metal substrate. Moreover, residual stresses during formation may also be sufficient to bend or flatten the nanoparticles, thereby avoiding the need for actual deformation. In addition, mechanical formation (e.g., pressing) is used on still other embodiments.
[0041] In accordance with another specific embodiment of the invention, heat shrinkable nanoparticles are employed other than shape memory materials. For example, collagen particles having diameters ranging from about 3 to 40 microns, and with a minimum diameter of about 0.1 micron, have been prepared by emulsifying and cross-linking native collagen. Rossler B, et al., "Collagen microparticles: preparation and properties," J.
Microencapsul.; 1995 Jan-Feb; 12(1): 49-57. The particle size is primarily controlled by the molecular weight of the collagen that was used, with an increase in denaturation of the collagen resulting in smaller particle sizes. Id. It is well known that collagen shrinks when heated. Haines, BM, "Shrinkage temperature in collagen fibres." Leather Conservation News, 3:1-5, 1987.
[0042] Magnetostrictive particles are also known, which change their size when a magnetic field is applied.
[0043] Hence, using the above and other techniques, nanoparticles can be formed which change shape when exposed to a suitable stimulus, such as heat. Consequently, once attached to tissues within the body, these nanoparticles can be activated to change shape.
[0044] For example, certain of these materials can be activated via localized application of heat or other stimulus (e.g., via a catheter or other insertable instrument).
[0045] Alternatively, certain of these materials can be activated using ex vivo stimulation to achieve an in vivo shape change. Sources of ex vivo stimulation include, for instance, oscillating magnetic fields, electromagnetic radiation (e.g., RF and microwave radiation), ultrasound, and so forth.
[0046] For example, magnetic nanoparticles can be heated by inductive heating using an oscillating magnetic field. To the extent that the material of interest is not intrinsically magnetic, magnetic nanoparticles, such as ferrite nanoparticles, can be added as susceptor particles. Alternatively, the material can be heated in situ using focused radiofrequency radiation, microwave radiation or ultrasound.
[0047] In some embodiments, the nanoparticles of the present invention are further provided with a drug, which can be delivered in vivo after self-assembly of nanoparticles.
[0048] As opposed to particles having only tissue binding ligands, the nanoparticies described herein contain interparticle binding ligands as well, allowing them to continue with interparticle assembly beyond the point of tissue contact. Consequently, self-assembled structures are formed in accordance with the present invention, which contain enhanced quantities of drugs.
[0049] "Drugs," "therapeutic agents," "pharmaceutically active agents," and other related terms may be used interchangeably herein and include genetic and non-genetic Therapeutic agents may be used singly or in combination. Therapeutic agents may be, for example, nonionic or they may be anionic and/or cationic in nature.
[0050] Exemplary non-genetic therapeutic agents for use in connection with the present invention include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone) and tissue plasminogen activator (TPA); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel (including particulate forms thereof such as ABRAXANE albumin-bound paclitaxel nanoparticles), 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD
peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;
(f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promotors; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (1) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; (o) agents that interfere with endogenous vasoactive mechanisms; (p) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (q) cytokines; (r) hormones; (s) inhibitors of HSP 90 protein (i.e., Heat Shock Protein, which is a molecular chaperone or housekeeping protein and is needed for the stability and function of other client proteins/signal transduction proteins responsible for growth and survival of cells) including geldanamycin;
(t) beta-blockers, (u) bARKct inhibitors, (v) phospholamban inhibitors, and (w) Serca 2 gene/protein.
[0051] Exemplary genetic therapeutic agents for use in connection with the present invention include anti-sense DNA and RNA as well as DNA coding for the various proteins (as well as the proteins themselves): (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic and other factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, endothelial mitogenic growth factors, epidermal growth factor, transforming growth factor a and (3, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ' ("TK") and other agents useful for interfering with cell proliferation. Also of interest is DNA encoding for the family of bone morphogenic proteins ("BMP's"), including BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.
[0052] Vectors for delivery of genetic therapeutic agents include viral vectors such as adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, replication competent viruses (e.g., ONYX-015) and hybrid vectors; and non-viral vectors such as artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)), graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers such as polyvinylpyrrolidone (PVP), SP 1017 (SUPRATEK), lipids such as cationic lipids, liposomes, lipoplexes, nanoparticles, or microparticles, with and without targeting sequences such as the protein transduction domain (PTD).
[0053] Numerous therapeutic agents, not necessarily exclusive of those listed above, have been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis. Such agents are useful for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/guanylate cyclase stimulants such as forskolin, as well as adenosine analogs, (d) catecholamine modulators including a-antagonists such as prazosin and bunazosine, (3-antagonists such as propranolol and a/(3-antagonists such as labetalol and carvedilol, (e) endothelin receptor antagonists, ( fl nitric oxide donors/releasing molecules including organic nitrates/nitrites such as nitroglycerin, isosorbide dinitrate and amyl nitrite, inorganic nitroso compounds such as sodium nitroprusside, sydnonimines such as molsidomine and linsidomine, nonoates such as diazenium diolates and NO
adducts of alkanediamines, S-nitroso compounds including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), as well as C-nitroso-compounds, 0-nitroso-compounds, N-nitroso-compounds and L-arginine, (g) Angiotensin Converting Enzyme (ACE) inhibitors such as cilazapril, fosinopril and enalapril, (h) ATII-receptor antagonists such as saralasin and losartin, (i) platelet adhesion inhibitors such as albumin and polyethylene oxide, (j) platelet aggregation inhibitors including cilostazole, aspirin and thienopyridine (ticlopidine, clopidogrel) and GP IIb/IIIa inhibitors such as abciximab, epitifibatide and tirofiban, (k) coagulation pathway modulators including heparinoids such as heparin, low molecular weight heparin, dextran sulfate and (3-cyclodextrin tetradecasulfate, thrombin inhibitors such as hirudin, hirulog, PPACK(D-phe-L-propyl-L-arg-chloromethylketone) and argatroban, FXa inhibitors such as antistatin and TAP (tick anticoagulant peptide), Vitamin K inhibitors such as warfarin, as well as activated protein C, (1) cyclooxygenase pathway inhibitors such as aspirin, ibuprofen, flurbiprofen, indomethacin and sulfinpyrazone, (m) natural and synthetic corticosteroids such as dexamethasone, prednisolone, methprednisolone and hydrocortisone, (n) lipoxygenase pathway inhibitors such as nordihydroguairetic acid and caffeic acid, (o) leukotriene receptor antagonists, (p) antagonists of E- and P-selectins, (q) inhibitors of VCAM-1 and ICAM-1 interactions, (r) prostaglandins and analogs thereof including prostaglandins such as PGE1 and PGI2 and prostacyclin analogs such as ciprostene, epoprostenol, carbacyclin, iloprost and beraprost, (s) macrophage activation preventers including bisphosphonates, (t) HMG-CoA
reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin and cerivastatin, (u) fish oils and omega-3-fatty acids, (v) free-radical scavengers/antioxidants such as probucol, vitamins C and E, ebselen, trans-retinoic acid and SOD mimics, (w) agents affecting various growth factors including FGF pathway agents such as bFGF antibodies and chimeric fusion proteins, PDGF receptor antagonists such as trapidil, IGF
pathway agents including somatostatin analogs such as angiopeptin and ocreotide, TGF-(3 pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF-P antibodies, EGF
pathway agents such as EGF antibodies, receptor antagonists and chimeric fusion proteins, TNF-a pathway agents such as thalidomide and analogs thereof, Thromboxane A2 (TXA2) pathway modulators such as sulotroban, vapiprost, dazoxiben and ridogrel, as well as protein tyrosine kinase inhibitors such as tyrphostin, genistein and quinoxaline derivatives, (x) MMP pathway inhibitors such as marimastat, ilomastat and metastat, (y) cell motility inhibitors such as cytochalasin B, (z) antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, which is a chlorinated purine nucleoside analog), pyrimidine analogs (e.g., cytarabine and 5-fluorouracil) and methotrexate , nitrogen mustards, alkyl sulfonates, ethylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas, cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, Epo D, paclitaxel and epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), rapamycin, cerivastatin, flavopiridol and suramin, (aa) matrix deposition/organization pathway inhibitors such as halofuginone or other quinazolinone derivatives and tranilast, (bb) endothelialization facilitators such as VEGF and RGD peptide, and (cc) blood rheology modulators such as pentoxifylline.
[0054] Numerous additional therapeutic agents useful for the practice of the present invention are also disclosed in U.S. Patent No. 5,733,925 assigned to NeoRx Corporation, the entire disclosure of which is incorporated by reference.
[0055] In some embodiments, drugs are linked to the nanoparticle portions using covalent coupling techniques such as those discussed below in conjunction with ligand coupling.
[0056] In some embodiments, drugs are provided within nanocapsules, which either correspond to the nanoparticle portion or which are coupled to the nanoparticle portion.
In this connection, polyelectrolyte nanocapsules have a number of desirable properties that make them useful for purposes of the present invention. For example, they permit the encapsulation of a wide variety of therapeutic and other agents, including small molecule pharmaceuticals, polypeptides (e.g., proteins such as enzymes), polynucleotides (e.g., DNA and RNA), and so forth. See, e.g., "Microencapsulation of Organic Solvents in Polyelectrolyte Multilayer Micrometer-sized Shells," S. Moya et al., .Iournal of Colloid and Interface Science, 216, 297-302 (1999). In addition, drugs can be loaded within these nanocapsules with high precision, for example, in multiples of 0.1 pico-gram per nanocapsule. See, e.g., "Assembly of Alternated Multivalent Ion/Polyelectrolyte Layers on Colloidal Particles," I.L. Radtchenko et al., Journal of Colloid and Interface Science, 230, 272-280 (2000).
[0057] Polyelectrolyte nanocapsules can be prepared using various known layer-by-layer techniques. Layer-by-layer techniques typically involve coating particles or droplets dispersed in aqueous media via electrostatic, self-assembly using charged polymeric (polyelectrolyte) materials. These techniques exploit the fact that the particles or droplets serving as templates for the polyelectrolyte layers each has a surface charge.
This renders the particles water dispersible and provides the charge necessary for deposition of subsequent polyelectrolyte layers. Multilayers are formed by repeated treatment with alternating oppositely charged polyelectrolytes, i.e., by alternating treatment with cationic and anionic polyelectrolytes. The polymer layers self-assemble onto the pre-charged solid/liquid particles by means of electrostatic, layer-by-layer deposition, thus forming a multilayered polymeric shell around the cores.
[0058] Many materials, such as polypeptides and polynucleotides, have an inherent surface charge that is present on particles made from the same. Other materials are uncharged. Such materials, however, can nonetheless be encapsulated by layer-by-layer techniques, for example, by providing them within particles or droplets which have a surface charge [0059] Polyelectrolytes are polymers having ionically dissociable groups, which can be a component or substituent of the polymer chain. Usually, the number of these ionically dissociable groups in the polyelectrolytes is so large that the polymers in dissociated form (also called polyions) are water-soluble. Specific examples of polycations include protamine sulfate polycations, poly(allylamine) polycations (e.g., poly(allylamine hydrochloride) (PAH)), polydiallyldimethylammonium polycations, polyethyleneimine polycations, chitosan polycations, eudragit polycations, gelatine polycations, spermidine polycations and albumin polycations. Specific examples of polyanions include poly(styrenesulfonate) polyanions (e.g., poly(sodium styrenesulfonate) (PSS)), polyacrylic acid polyanions, sodium alginate polyanions, eudragit polyanions, gelatine polyanions, hyaluronic acid polyanions, carrageenan polyanions, chondroitin sulfate polyanions, and carboxymethylcellulose polyanions.
[0060] By using polyelectrolytes that are degradable, the release of enclosed drug can be controlled via the degradation of the nanocapsule walls. Otherwise, release is typically controlled by diffusion.
[0061] The wall thickness provided by layer-by-layer techniques will frequently range, for example, from 4 to 50 nm. The size of the resulting nanocapsules can vary widely, depending upon the size of the template, and will frequently range, for example, from 50 to 1000 nanometers in largest dimension, but dimensions beyond these values may also be provided.
[0062] Techniques other than direct encapsulation are also available for encapsulating agents of interest within polyelectrolyte shells. For example, various techniques take advantage of gradients across the nanocapsule wall to effect precipitation or synthesis of a desired substance within the shell. For instance, as a general rule, large macromolecules typically cannot penetrate polyelectrolyte multilayers, while small molecules, on the other hand, can. Accordingly, the presence of macromolecules inside the nanocapsules can lead to a difference in the physico-chemical properties between the inside and the outside of the nanocapsule, for example, providing gradients in pH and/or polarity that can be used to trap materials within the nanocapsules.
[0063] Moreover, charged drugs can be substituted for one or more of the polyelectrolyte layers, thereby incorporating the drug between polyelectrolyte layers within the capsule shell.
[0064] Materials instead of, or addition to, drugs can also be encapsulated using polyelectrolyte deposition techniques. As a specific example, the encapsulation of magnetite (Fe304) nanoparticles inside poly(styrene sulfonate)/poly(allylamine hydrochloride polyelectrolyte multilayers has been reported. Micron and submicron sized nanocapsules are made by means of layer-by-layer adsorption of oppositely charged polyelectrolytes (PSS, PAH) on the surface of colloidal template particles (e.g., weakly cross-linked melamine formaldehyde particles having a precipitated PAH-citrate complex) with subsequent degradation of the template core. This leaves free PAH in the core, which creates a pH gradient across the shell. At this point, (a) negatively charged, preformed magnetic particles of sufficiently small size (e.g., Fe304 nanoparticles) can be used to impregnate the nanocapsules whereupon they are held by electrostatic interactions, or (b) magnetic material (e.g., Fe304) can be selectively synthesized inside the core based on the pH gradient and on presence of dissolved PAH in the nanocapsule.
The resulting nanocapsules are easily driven by a magnetic field. Additional information can be found, for example, in "Micron-Scale Hollow Polyelectrolyte Nanocapsules with Nanosized Magnetic Fe304 Inside," Materials Letters, D.G. Shchukin et al. (in press), the disclosure of which is hereby incorporated by reference. If desired, drugs can be incorporated into such nanocapsules along with the magnetic material.
[0065] Further information on the formation of nanocapsules having polyelectrolyte shells can be found, for example, in United States Patent Application Serial No.
10/638,739, United States Patent Application Pub. No. 2002/0187197, WO
99/47252, WO 00/03797, WO 00/77281, WO 01/51196, WO 02/09864, WO 02/09865, WO
02/17888, "Fabrication of Micro Reaction Cages with Tailored Properties," L.
Dahne et al., J. Am. Chena. Soc., 123, 5431-5436 (2001), "Lipid Coating on Polyelectrolyte Surface Modified Colloidal Particles and Polyelectrolyte Nanocapsules," Moya et al., Macrornolecules, 33, 4538-4544 (2000); "Controlled Precipitation of Dyes into Hollow Polyelectrolyte Nanocapsules," G. Sukhorukov et al., Advanced Materials, Vol.
12, No.
2, 112-115 (2000), "A Novel Method for Encapsulation of Poorly Water-soluble Drugs:
Precipitation in Polyelectrolyte Multilayer Shells," I.L. Radtchenko et al., International Jouf-nal of Pharrnaceutics, 242, 219-223 (2002), the disclosures of which are hereby incorporated by reference.
[0066] For nanoparticles containing encapsulated drugs, drug release can occur, for example, due to one or more of the following mechanisms: (a) as a result of diffusion through the encapsulation layer or layers, (b) as a result of biodegradation of the encapsulation layer(s), and (c) as a result of increased permeability or breakage of the encapsulation layer(s), for example, due to external stimulation using radiofrequency radiation, microwave radiation, oscillating magnetic fields, or ultrasound (which can assist with delivery, for example, via the generation of thermal energy or via acoustic cavitation). For example, using Magnetic Resonance Imaging (MRI) fields at diagnostic levels, researchers at the Biological Systems Office (BSO), Johnson Space Center have heated microcapsules containing ferromagnetic particles to a temperature that is sufficient to melt holes in the outer skin of the microcapsules. Similarly, ferromagnetic nanoparticles within polyelectrolyte capsules (see above) could be likewise heated to the point where they penetrate the polyelectrolyte shell, so long shell materials are chosen which have melting temperatures that are below the temperatures attained by the ferromagnetic nanoparticles during heating.
[0067] For nanoparticles having attached drugs, release can occur, for example, due to one or more of the following mechanisms: (a) as a result of biodegradation of the nanoparticles, (b) as a result of biodegradation of a coupling species between the nanoparticles and the drugs, (c) by selection of a thermosensitive coupling, which is severed by heating the particle to which it is attached or the environment that it occupies (e.g., by exposure to ultrasound, alternating magnetic fields and radio- and microwave-frequency electromagnetic fields).
[0068] Some embodiments of the invention involve nanoparticles which can be heated in vivo to produce localized cell death, for example, by exposing the assembled nanoparticles to ultrasound, alternating magnetic fields and radio- and microwave-frequency electromagnetic fields as discussed above. Mechanisms of cell death due to heating include necrotic processes and apoptotic process. Necrotic cells undergo swelling and rupture, while apoptotic cells are removed by phagocytosis because they display markers on their cell surfaces that target them for selective e.limination.
Mild hyperthermia (e.g., 43 C for 30 to 60 minutes) is known to enhance apoptosis in normal and cancerous cell populations, while higher teinperatures (e.g., higher than 56 C) trigger the necrotic process. For more information see, e.g., Andrea Jordan et al., "Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia," Journal of Magnetism and Magnetic Materials, 225 (2001) 118-126; and Kuznetsov AA et al., "'Smart' mediators for self-controlled inductive heating," European Cells and Materials, Vol. 3. Suppl. 2, 2002 (pages 75-77).
[0069] As previously noted, an important feature of the present invention is that the nanoparticles self assemble in vivo. Self assembly is directed in the present invention by providing the nanoparticles with ligands, which attach to tissue in the body or which attach to ligands on other nanoparticles.
[0070] The ligands for binding the nanoparticles of the present invention to tissue will depend upon the tissue being targeted. Tissue attachment ligands can be selected, for example, the following species (or portions thereof): ankyrins, cadherins, members of the immunoglobulin superfamily (which includes a wide array of molecules, including NCAMs, ICAMs, VCAMs, and so forth), selectins (L-, E- and P- subcalsses), proteoglycans, connexins, mucoadhesives, sialyl Lex, plant or bacterial lectins (adhesion molecules which specifically bind to sugar moieties of the epithelial cell membrane), laminins, dermatan sulphate, entactin, fibrin, fibronectin, vimentin, collagen, glycolipids, glycophorin, glycoproteins, heparan sulphate, heparin sulphate, hyaluronic acid, keratan sulphate, spektrin, von Willebrand factor, vinculin, vitronectin, and polypeptides and proteins containing various peptide sequences including RGD tripeptide (i.e., ArgGlyAsp, which has been identified to be responsible for some of the cell adhesion properties of fibronectin, laminin, collagen I, collagen IV, thrombospondin, and tenascin), REDV
tetrapeptide (i.e., Arg-Glu-Asp-Val ), which has been shown to support endothelial cell adhesion but not that of smooth muscle cells, fibroblasts, or platelets), and YIGSR
pentapeptide (i.e., TyrIleGlySerArg, which promotes epithelial cell attachment, but not platelet adhesion). More information on these and other peptides can be found in U.S.
Patent No. 6,156,572 and U.S. Patent Application No. 2003/0087111.
[0071] In this connection, small oligopeptides (e.g., two to 12 amino acids) are normally rapidly removed from the body, with various processes involved in their clearance. See Meijer DK, et al., "Disease-induced drug targeting using novel peptide-ligand albumins,"
JControl Release; 2001 May 14;72(1-3):157-64. However, by coupling of such peptides to nanoparticles, elimination via various pathways is expected to be reduced or prevented.
[0072] Thus, interactions between ligands and tissues are selective in the present invention, with beneficial tissue-ligand interactions including ligand-cell receptor interactions, antibody-antigen type interactions (e.g., using whole antibodies or antibody fragments), interactions between enzymes and coenzymes and inhibitors, and nucleic acid hybridization, among other interactions.
[0073] A few specific examples of tissue targeting ligands are discussed in detail below.
[0074] For example, histologic features of vulnerable plaques include a large lipid core, a thin fibrous cap, intraplaque hemorrhage, and an increased number of inflammatory cells, particular monocyte-macrophages. Plaque is composed of a core (containing, for example, lipid and cholesterol crystals, macrophages, foam cells, necrotic cell debris, plasma proteins and degenerating blood elements) that is separated from the lumen by a layer of fibrous tissue, also known as a fibrous cap (containing, for example, smooth muscle cells, macrophages, foam cells, collagen, elastin, proteoglycans and other extracellular matrix [ECM] components).
[0075] Hence, where the targeted tissue is atherosclerotic plaque, ligands can be selected based on the presence or expression of various molecular species in the ECM
components of the plaque. In particular, plaque remodelling is known to occur by matrix metalloproteinases (MMPs), specifically MMP-1, MMP-2, MMP-3 and MMP-9. See Zaltsman AB et al., "Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity," Arterioscler Thromb Vasc Biol; 1999 Jul;
19(7):1700-7.
Moreover, various tissue inhibitors of metalloproteinases (TIMPs) at known to preferentially bind to matrix metalloproteinases. For instance, TIMP-1 preferentially binds to MMP-1 and MMP-9, TIMP-2 preferentially binds to MMP-2, and TIMP-3 preferentially binds to MMP-1 and MMP-9. Id. Mutants of TIMPs have also been reported which have enhanced binding affinity to MMPs, including MMP-2 and MMP-3.
Shuo Wei et al., "Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain," J. Biol. Chem., Vol. 278, Issue 11, 9831-9834, March 14, 2003. Accordingly, in one embodiment of the invention, TIMPs , or analogs or derivatives thereof, are used for targeting plaque.
[0076] Antibodies are also available, or they can be generated using known techniques, for targeting MMPs in the fibrous cap. For example, rabbit anti-MMP-1 (which binds to MMP-1 but does not cross react with MMP family members MMP-2A, MMP-2B, and MMP-3, MMP-9), is available from Research Diagnostics Inc., Flanders NJ, USA.
Also available form Research Diagnostics Inc. are mouse anti-human MMP-3 monoclonal antibody, rabbit Anti-MMP-3 antibody, mouse anti-human MMP-9 monoclonal antibody, and rabbit anti-MMP-9 antibody. Accordingly, in another embodiment of the invention, anti-MMP antibodies, or fragments, analogs or derivatives thereof, are used for targeting plaque.
[0077] Type III collagen in the fibrous cap is another target for self-assembly, based on its exposure and the loss of the basement membrane that overlays the cap. See, e.g., Kolodgie FD et al., "Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion," Arterioscler Thromb Vasc Biol; 2002 Oct 1;
22(10):1642-8. Antibodies are also available, or can be generated, for use in forming ligands that bind to collagen III. For example, mouse collagen type III
monoclonal antibody, is available from Chemicon International, Inc, Temecula, CA, USA and rabbit collagen III antibody and mouse collagen III antibody are available from Abcam; Ltd., Cambridge, UK. Hence, in another embodiment of the invention, anti collagen type III
antibodies, or fragments, analogs or derivatives thereof, are used for targeting plaque.
[0078] Another target for self-assembly is lipoprotein (a) matrix metalloproteinase-derived F2, since this is present in regions of increased matrix metalloproteinase 2 and matrix metalloproteinase 9. See Fortunato JE et al., "Apolipoprotein (a) fragments in relation to human carotid plaque instability," J Vasc Surg; 2000 Sep;
32(3):555-63.
[0079] Apoptosis is common in advanced human atheroma and contributes to plaque instability. Annexin V (a member of the annexin family of calcium-dependent phospholipid-binding proteins) has a high affinity for exposed phosphatidylserine on apoptotic cells. See Kolodgie FD, et al., "Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque," Circulation. 2003 Dec 23;108(25):3134-9. In addition, benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone (Z-VAD-fmk), is known to be a potent inhibitor of the enzymatic cascade intimately associated with apoptosis. See Haberkorn U, et al., "Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone,"
Nucl Med Biol. 2001 Oct;28(7):793-8.
[0080] Moreover, the presence of an inflammatory stimulus increases the expression of CC (cysteine-cysteine motif) chemokine receptor (CCR)-2 on monocytes and macrophages, as well as somatostatin receptors on T lymphocytes. Monocyte chemoattractant protein (MCP)-1 binds with high affinity to CCR-2'and is thus used to detect subacute and chronic inflammatory lesions. See Blankenberg FG, et al., "Development of radiocontrast agents for vascular imaging: progress to date,"
Am J
Cardiovasc Drugs; 2002;2(6):357-65. In addition, octreotide or depreotide are used to detect activated T lymphocytes which may identify vulnerable plaque. Id. MCP-1 and fluoro-2-deoxyglucose have been shown in animal models to be effective in identifying macrophage infiltration and metabolic activity in atheromatous lesions, respectively. Id.
[0081] Furthermore, MDC, fractalkine, and TARC, which are chromosome 16q13 chemokines, are expressed in atherosclerotic lesions. Greaves DR et al., "Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions," Arterioscler Thromb Vasc Biol; 2001 Jun;21(6):923-9.
[0082] Peptides such as endothelin are also being explored as agents for collecting at unstable atherosclerotic plaque. Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q JNucl Med; 2003 Dec; 47(4):279-91.
[0083] Consequently ligands containing annexin V, Z-VAD-fmk, (MCP)-1, octreotide, depreotide, fluoro-2-deoxyglucose, MDC, fractalkine, TARC and endothelin, among others, or fragments, analogs or derivatives thereof, are used in certain embodiments of the invention for targeting plaque.
[0084] In addition to plaque, apoptosis is also associated with cancer, acute cerebral and myocardial ischemic injury and infarction, immune mediated inflammatory disease and transplant rejection. See Blankenberg FG, "Recent advances in the imaging of programmed cell death,", Curr Pharrn Des, 2004;10(13):1457-67 and Blankenberg F, et al., "Imaging cell death in vivo," Q JNucl Med; 2003 Dec;47(4):337-48. Hence, in some embodiments of the invention, ligands containing species with a high affinity for apoptotic cells, such as annexin V and Z-VAD-fmk (or fragments, analogs or derivatives thereof), among others, are used for the treatment and/or diagnosis of these conditions as well.
[0085] With respect to infarcts, antimyosin Fab, a Fab monoclonal antibody fragment, is known to provide great specificity for the detection of inyocardial necrosis, irrespective of the cause of injury. Khaw BA, "The current role of infarct avid imaging,"
Senain Nucl Med; 1999 Jul;29(3):259-70. For example, five patients with a history of remote infarction and acute necrosis were reported to show antimyosin uptake only in regions concordant with the acute episodes of infarction, and radiolabeled antimyosin Fab localized in neither old infarcts nor normal, noninfarcted myocardium. Khaw BA
et al., "Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab," JNucl Med; 1987 Nov; 28(11):1671-8. Consequently ligands containing antimyosin Fab, or fragments, analogs or derivatives thereof, are used in some embodiments of the invention for targeting infarcts.
[0086] Autologous leukocytes concentrate at inflammatory and infectious sites, as do cytokines (e.g., IL-1, IL-2) and chemokines (e.g., IL-8, PF-4, MCP-1, NAP-2), complement factors (e.g., C5a and C5adR), chemotactic peptides (e.g., fMLF), other chemotactic factors (e.g., LTB4), as well as antagonists to the tuftsin receptor. van Eerd JE, et al., "Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation," Q JNucl Med; 2003 Dec; 47(4):246-55 and Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q
JNucl Med; 2003 Dec; 47(4):279-91. Hence, ligands containing these species, or fragments, analogs or derivatives thereof, are used in some embodiments of the invention for targeting inflammatory and infectious sites.
[0087] Expression of alpha(v)beta(3) integrin is increased in activated endothelial cells and vascular smooth muscle cells after vascular injury, whereas alpha(v)beta(3) integrin is minimally expressed on smooth muscle cells and is not expressed on quiescent epithelial cells. See Blankenberg FG, et al., "Development of radiocontrast agents for vascular imaging: progress to date," Ana JCardiovasc Drugs; 2002;2(6):357-65.
Moreover, it is reported that radiolabeled high-affmity peptides can be used to target the alpha(v)beta(3) integrin and visualize areas of vascular damage. Id. Hence, ligands containing this peptide or fragments, analogs or derivatives thereof, are used in accordance with some embodiments of the invention for targeting vascular damage.
[0088] In vascular damage, sub-endothelial regions are exposed, such as the basal lamina/basement membrane (which is a network of specialized ECM proteins, including type IV collagen, fibronectin, laminin, heparan sulfate proteoglycan, and nidogen which is a sulphated glycoprotein), and for larger vessels, there is a tunica media (which is composed of smooth muscle cells within a matrix of elastin, type I, III and V
collagen, proteogyycan, and so forth). Hence, ligands for targeting vascular damage also include various integrins which bind to theses species. Integrins recognize a wide variety of extracellular matrix components and cell-surface receptors, including collagen, fibronectin, vitronectin, laminin, fibrinogen, and adhesion molecules including intracellular adhesion molecules (ICAMS) and vascular adhesion molecules (VCAMS).
Members of the integrin family of cell-surface receptors are expressed on virtually all mammalian cells and mediate adhesion of cells to one another and to the extracellular matrix. Additional information can be found, for example, in U.S. Patent Appln. No.
2002/0058336 and U.S. Pat. Appln. No. 2003/0007969, the disclosures of which are hereby incorporated by reference.
[0089] For thromboembolic disease, peptides which bind to various components of thrombi are known, including peptide analogs of fibrin or fragments of fibronectin which have a distinct binding domain for fibrin, linear and cyclic peptide antagonists of the glycoprotein IIb/IIIa receptor on platelets, naturally occurring antagonists of this receptor which are found in venoms, analogues of laminin and thrombospondin which bind to other receptors on platelets, and peptides which target thrombin that which is sequestered within a fibrin clot. Knight LC, "Non-oncologic applications of radiolabeled peptides in nuclear medicine," Q JNucl Med; 2003 Dec; 47(4):279-91. In certain of these embodiments, the nanoparticles are provided with agents to help resolve and heal the thrombus, such as plasmin, Tissue Plasminogen Activator (TPA), growth factors and/or cell adhesion proteins, such as fibronectin, RGD peptides, etc.
[0090] Nanoparticles in accordance with the present invention are also provide,d with ligands for interparticle binding. As with ligands for tissue binding, interactions between the interparticle binding ligands are selective and include such beneficial interactions as ligand-receptor type interactions, antibody-antigen type interactions, nucleic acid interactions, and cell receptive mimetic binding, among others. A specific example of an interparticle ligand binding pair is the combination of a synthetic peptide sequence (preferable having no in vivo counterpart) and an antibody (or antibody fragment) for the same.
[0091] Once a ligand is selected, it must be associated with a nanoparticle portion, for example, those described above. In this regard, recent years have seen an enormous increase in the development of techniques for coupling polypeptides, polysaccharides, polynucleotides, and other biopolymers as well and small molecules to solid supports.
For example, coupling techniques are widely practiced for use in diagnostic applications, for instance, affinity chromatography.
[0092] In general, the immobilization technique selected will depend upon the chemical characteristics of the ligand (e.g., whether it is a polypeptide, polysaccharide, polynucleotide, small molecule substance, etc.) and the nanoparticle (e.g., whether it is organic or inorganic, metallic or non-metallic). Obviously, the technique should not destroy the binding ability of the ligand.
[0093] Depending on the available reactive groups within the selected ligand, several well known coupling chemistries are readily available for ligand immobilization, including those based on various condensation, addition, and substitution reactions. For example, amine, thiol and aldehyde coupling chemistries are well known in the coupling art. Most macromolecules contain amine groups, which can be used in amine coupling.
The choice of thiol coupling depends on the availability of thiol groups on the ligand.
However, it is relatively easy to provide a given ligand with thiol groups, if necessary.
Thiol chemistry generally considered to be more robust than the amine chemistry, so the coupling conditions are less critical. The choice of aldehyde coupling is made, for instance, with polysaccharides and glycoconjugates. With respect to streptavidin-biotin coupling, nucleic acids, polysaccharides and glycoconjugates are relatively easy biotinylated using a variety of reagents and functional groups.
[0094] With respect to the nanoparticle portions, those that are polymeric in nature frequently have organic functional groups, which can directly participate, or can be readily modified to participate, in coupling chemistries known in the art for attaching ligands, including those discussed above.
[0095] Where the nanoparticles are metallic or ceramic in nature, the surfaces are typically derivatized prior to coupling. For example, using techniques such as those described in U.S. Serial No. 10/830,772, ligands may be covalently coupled to a nanoparticle surface by a method that comprises: (a) halogenating the surface;
and (b) reacting the halogenated surface with a reactive molecule that is covalently reactive with the chlorinated surface region. For example, the surface region may be halogenated by exposing the exposing the surface region to a reactive chloride, for example, a reactive chloride selected from the following: SiC14 (silicon tetrachloride), TiC14 (titanium tetrachloride), GeC14 (germanium tetrachloride), SnCI~ (tin tetrachloride), (vanadium tetrachloride), MoCl5 (molybdenum pentachloride), WCl6 (tungsten hexachloride), BC13 (boron trichloride), and PCl5 (phosphorus pentachloride).
According to a specific example, a surface region (e.g., a metal or a ceramic surface region with available hydroxide groups) is reacted with silicon tetrachloride as a halogenating agent (in this instance, a chlorosilanization agent). This reaction scheme can be represented, for example, as follows:
M-OH + SiC1~--> M-O-SiC13 + HCI, where M corresponds to the metal or ceramic surface. Once they are produced on the surface, the chorosilane groups are then exposed to a molecule that is reactive with the same (e.g., species comprising hydroxyl groups), thereby forming a covalently coupled molecular species.
[0096] The above scheme can be conducted on a wide variety of surfaces, including various metallic and ceramic surfaces, so long as surface hydroxyl groups are available for reaction. This scheme can also be conducted on various metals which form native oxide layers. In this regard, controlled native oxide layers can be formed on most metals used today in medical devices. This technology is well known. The above reaction scheme can also be conducted on surface regions which have been pretreated to establish hydroxyl groups thereon. For example, in some embodiments, a surface region, for example, a polymeric surface region, is pretreated by subjecting it to a glow discharge step. The resulting surface region, which is hydroxylated during the glow discharge step, is then available for reaction in accordance with the above scheme.
[0097] Ligand attachment need not be covalent. For example, it is known from Michel R., et al., "Self-organized molecular assembly: patterning of surfaces at the micro- and nano-scale for biological applications," Langmuir, 2002, 18, 3281-3287, that alkane phosphates from aqueous solution will adsorb onto certain metal oxides, such as titanium or niobium oxide. Due to the presence of titanium oxide on nickel-titanium alloy surfaces, dodecylphosphate (DDP) is expected to be readily adsorbed by self-assembly from aqueous solutions of its ammonium salt, rendering the titanium oxide surface hydrophobic and hence protein-adsorbing. (In alternative embodiments, a thin layer of pure titanium oxide is formed at the nanoparticle surface.) Subsequently, polypeptide containing molecules, including proteins, are adsorbed to the surface.
[0098] If desired, ligands can be coupled to only a portion of the nanoparticle surface.
For example, lithographic masking techniques can be used to prevent contact with certain portions of the nanoparticles. As another exainple, see also, for example, A K
Salem et al. "Multifunctional nanorods for gene delivery," Nature Materials, Vol. 2, 2003, pp 668-671, which describes a non-viral gene-delivery system based on multisegment bimetallic nanorods (Au/Ni) that can simultaneously bind compacted DNA
plasmids and targeting ligands in a spatially defined manner.
[0099] Using the above and other techniques, a wide variety of ligands can be adsorbed or covalently coupled to a wide range of nanoparticle potions. For more information on ligand coupling, see, for example, Mohammed Aslam PhD and Alastair H. Dent, Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences, Nature Publishing Group, 1998; Yuri Lvov et al., Protein Architecture: Interfacing Molecular Assemblies and Immobilization Biotechnology, Marcel Dekker, 1999; and Shtilman, MI, Inamobilization on Poly zers, VSP International Science Publishers, 1993; the disclosures of which are incorporated by reference.
[0100] In many embodiments of the invention, it is desirable to non-invasively image the nanoparticles once they are assembled in vivo. Among currently available non-invasive imaging techniques are included magnetic resonance imaging (MRI), x-ray fluoroscopy and scintigraphic imaging, among others.
[0101] Magnetic resonance imaging (MRI) produces images by differentiating detectable magnetic species in the portion of the body being imaged. For contrast-enhanced MRI, it is desirable that the contrast agent have a large magnetic moment, with a relatively long electronic relaxation time. Based upon these criteria, contrast agents such as Gd(III), Mn(II) and Fe(III) have been employed. Gadolinium(III) has the largest magnetic moment among these three and is, therefore, a widely-used paramagnetic species to enhance contrast in MRI. Chelates of paramagnetic ions such as Gd-DTPA
(gadolinium ion chelated with the ligand diethylenetriaminepentaacetic acid) have also been employed as MRI contrast agents. In accordance with certain embodiments of the invention, paramagnetic ion chelates can be attached to selected nanoparticle portions using coupling techniques such as those described above.
[0102] As seen above, many species useful as tissue targeting ligands are currently available in radiolabeled form, allowing them to be imaged. Alternatively, techniques are well-known for providing ligands with radiolabeled atoms.
[0103] With respect to x-ray based fluoroscopy, some nanoparticles such as metallic nanoparticles are inherently more absorptive of x-rays than surrounding tissue.
Alternatively, the nanoparticles of the present invention can be provided with contrast agents, in certain embodiments, such as metals (e.g., tungsten, platinum, tantalum, iridium, gold, or other dense metal), metal compounds (e.g., barium sulfate, bismuth subcarbonate, bismuth trioxide, bismuth oxychloride, etc.) or iodinated compounds (e.g., iopamidol, iothalamate sodium, iodomide sodium).
[0104] Ultrasound uses high frequency sound waves to create an image of living tissue.
A sound signal is sent out, and the reflected ultrasonic energy, or "echoes,"
used to create the image. Ultrasound imaging contrast agents are materials that enhance the image produced by ultrasound equipment. Ultrasonic imaging contrast agents introduced into the compositions of the present invention can be, for example, echogenic (i.e., materials that result in an increase in the reflected ultrasonic energy) or echolucent (i.e., materials that result in a decrease in the reflected ultrasonic energy). Suitable ultrasonic imaging contrast agents for use in connection with the present invention include solid particles ranging from about 0.01 to 50 microns in largest dimension (e.g., the nanoparticles of the present invention may provide sufficient contrast in some instances). In other embodiments, nanobubbles (e.g., air filled nanocapsules) are used.
[0105] Hence, using the above and other techniques known to those of ordinary skill in the art, nanoparticles can be fabricated and subsequently injected into the vasculature where they attach to diseased or abnormal structures that have an identifiable marker, which may appear, for example, on the endothelium, on exposed basement membrane, on exposed extracellular matrix, and so forth. Further particles then self-assemble into a structure over the particles that initially attach to the tissue. The shape of the endovascular structure assembled will depend, for example, on the shape of the particles, the locations of the ligands, and so forth.
[0106] In some embodiments, the self-assembled structures act as stabilizing or isolating structures over diseased or aberrant tissue. For example, in some embodiments, vulnerable plaque (i.e., plaque at risk for rupture) is stabilized by the self-assembly of what effectively amounts to a patch over the plaque. Additionally, if the nanoparticles have the property that they can partition into the plaque (e.g. because they have lipophilic character that carbon nanotubes, among other particles, may possess) they may self assemble in the plaque, which may, for example, allow the assembly to be better retained, stabilize the plaque by the presence of a large structure, and/or release a variety of therapeutic agents (e.g., anti-inflammatory agents to mitigate the processes that cause the plaque to become unstable, agents to enhance healing of the plaque, agents and polymeric precursors that can gel the components of the plaque for stabilization, for instance, by crosslinking of the polymeric precursors upon release, and so forth).
Furthermore, the self assembled structure may be used as a diagnostic to locate the position of vulnerable plaques. Depending on the nature of the nanoparticles and their components, they could be visible by MRI (e.g., by using paramagnetic particles) or by catheters with spectroscopic (e.g. near infrared) detectors. For an example of the latter technique, see, e.g., PW Barone, et al. "Near-infrared optical sensors based on single-walled carbon nanotubes," Nature Materials 4 (2005) 86-92.
[0107] In some embodiments, the self-assembled structures perform a mechanical function. For instance, the structures can contract and/or expand upon activation (e.g., by exploiting shape memory or other shape-change properties of the individual particles).
Triggers for activating the shape change properties of the material include ultrasound, radiofrequency radiation, microwave radiation, or oscillating magnetic fields as discussed above. Further, a molecular aggregate with an interparticle binding ligand and a further ligand may be used to cause a conformation change when an injected agent or an agent that circulates in blood binds to this further ligand. For example, various molecules are known which change in conformation upon binding to other agents. Molecules are also known which change in conformation upon exposure to energy, which causes partial or full denaturation.
[0108] Using such techniques, in the case where a structure is self-assembled over obstructing plaque or restenotic structures, the structure is then expanded to increase the vessel diameter by activating the shape memory property of the self-assembled particles.
In this instance, the self-assembled structure is acting as an expanded stent segment. In one specific embodiment, a U-shaped shape memory rod is employed as the nanoparticle portion and ligands are provided at the ends of the U. These particles then undergo shape change and open up when triggered (e.g., by heating).
[0109] This shape change can also be used to impose a force for shrinking damaged and dilated tissue. A specific example of a beneficial shrinking structure is the case where an adherent structure is self-assembled over scarred heart muscle (e.g. from an old infarct), and then activated to contract (e.g., linear shape memory rods are employed which become U-shaped upon triggering). This contraction reshapes the heart, reducing the ventricular volume, increasing ejection fraction, and leading to positive remodelling of the heart. The reduced volume increases the force of heart contraction and ejection fraction consistent with Starling's law of the force of heart contraction.
This concept is practiced on gross scale by surgical interventions by removing the heart muscle, by ventricular reduction using the Battista or Dorr procedures, or by shrinking the scarred tissue and patching using processes such as those available from Hearten Medical, Irvine, CA, USA.
[0110] Self assembled structures can also be triggered, using techniques such as those discussed above, to release drugs or other beneficial agents that are contained in or attached to the nanoparticles. For example, these agents can be antirestenosis agents in order to treat plaque. As another example, these agents can correspond to components of single- or multi-component adhesives or glues (e.g., fibrinogen, thrombin, cyanoacrylate adhesive, etc.) to further stabilize vulnerable plaque and for aneurysmal management. As yet another example, these agents can correspond to growth factors to repair vascular tissue or to revascularize injured and/or scarred tissue, such as heart muscle following infarct.
[0111] In further embodiments, the self-assembling compositions of the present invention are used to target diseased or infected tissue, including tissue infected with bioterror agents. Upon activation the self-assembled structures (most likely in capillary beds), a drug or other argent is released to treat the disease or infection.
[0112] As a specific example, inhalation of infectious agents into the lungs is expected to result in changes of the endothelium of the capillary beds in the lungs. These aberrant endothelium can be targeted for the formation of self-assembled structures that will release anti-infectious agents at only the local site of infection. For instance, as noted above, autologous leukocytes concentrate at inflammatory and infectious sites, as do cytokines, chemokines, complement factors, chemotactic peptides, other chemotactic factors, as well as antagonists to the tuftsin receptor. Hence, ligands for nanoparticles that are intended for delivery at sites of local infection can be selected from these species.
The above and other techniques could allow the use of relatively toxic agents, since they are only released locally at the site of infection.
[0113] Self assembled endovascular structures in accordance with the present invention can also be used as a scaffolds for tissue repair. These structures would contain ligands that bind endogenous cells or injected cells. For example, as indicated above, peptides having affinity for the alpha(v)beta(3) integrin can be used to target areas of vascular damage. Moreover, integrins can also be used to target areas of vascular damage, as they recognize a wide variety of extracellular matrix components and cell-surface receptors, as previously noted. Preferred nanoparticles for forming self assembled scaffolds for tissue repair include nanoparticles of extracellular matrix materials such as collagen (e.g., type IV collagen), glycosaminoglycans, synthetic particles providing a coating with ECM-like materials to encourage healing, and so forth. The self assembled nanoparticles can also be provided with drugs or other agents which are released to attract and/or promote growth of the desired endogenous cell type.
[0114] Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.
Claims (28)
1. An injectable composition comprising self-assembling nanoparticles, said self-assembling nanoparticles comprising: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion that cause preferential binding and accumulation of the nanoparticles at one or more targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle, which result in interparticle binding at the one or more targeted tissue locations.
2. The composition of claim 1, wherein at least one of the first and second interparticle binding ligands is activated in vivo at said one or more targeted tissue locations.
3. The composition of claim 1, wherein said nanoparticle portions are selected from spherical nanoparticle portions, plate-shaped nanoparticle portions, and elongated nanoparticle portions.
4. The composition of claim 1, wherein said nanoparticle portions are inorganic nanoparticle portions.
5. The composition of claim 4, wherein said inorganic nanoparticle portions are metallic nanoparticle portions.
6. The composition of claim 1, wherein said nanoparticle portions are organic nanoparticle portions.
7. The composition of claim 6, wherein said organic nanoparticle portions are polymeric nanoparticle portions.
8. The composition of claim 1, wherein the shape of said nanoparticle portions can be changed in vivo by administering a triggering procedure.
9. The composition of claim 8, wherein said nanoparticle portions have a shape memory.
10. The composition of claim 9, wherein said nanoparticle portions are formed from shape memory metals or shape memory polymers.
11. The composition of claim 9, wherein said nanoparticle portions expand upon triggering said shape memory.
12. The composition of claim 9, wherein said nanoparticle portions contract upon triggering said shape memory.
13. The composition of claim 8, wherein said nanoparticle portions are formed from a heat-shrinkable material.
14. The composition of claim 1, wherein said self-assembling nanoparticles comprise a releasable adhesive species.
15. The composition of claim 1, wherein said self-assembling nanoparticles comprise a drug that is released in vivo and subsequent to nanoparticle self-assembly.
16. The composition of claim 15, wherein said drug is covalently coupled to said nanoparticle portion.
17. The composition of claim 15, wherein said drug is encapsulated and attached to said nanoparticle portion.
18. The composition of claim 15, wherein said nanoparticle portion comprises a drug.
19. The composition of claim 15, wherein said nanoparticle portion comprises an encapsulated drug.
20. The composition of claim 15, wherein said drug is selected from an anti-restenosis drug, an anti-thrombotic drug, growth factors, an anti-inflammatory drug, cell adhesion proteins, and combinations of the same.
21. The composition of claim 1, wherein said self-assembling nanoparticles comprise magnetic nanoparticles.
22. The composition of claim 1, wherein said tissue binding ligands are selected from antibodies, integrins, cell receptor mimetics and combinations of the same.
23. The composition of claim 1, wherein said first and second interparticle binding ligands comprise antibody-antigen pairs.
24. A kit for self-assembly of nanoparticles in vivo comprising:
(a) a first injectable composition comprising first self-assembling nanoparticles that comprise (i) a first nanoparticle portion (ii) tissue binding ligands attached to the first nanoparticle portion that cause preferential binding and accumulation of the first self-assembling nanoparticles at one or more targeted tissue locations upon injection of the first composition into the body, and (iii) first interparticle binding ligands attached to the first nanoparticle portion to promote interparticle binding; and (b) a second injectable composition comprising second self-assembling nanoparticles which comprise (i) a second nanoparticle portion and (ii) second interparticle binding ligands attached to the second nanoparticle portion that preferentially bind to the first interparticle binding ligands of the first nanoparticles upon injection of the second composition into the body, wherein said first and second nanoparticle portions can be formed from the same or different materials.
(a) a first injectable composition comprising first self-assembling nanoparticles that comprise (i) a first nanoparticle portion (ii) tissue binding ligands attached to the first nanoparticle portion that cause preferential binding and accumulation of the first self-assembling nanoparticles at one or more targeted tissue locations upon injection of the first composition into the body, and (iii) first interparticle binding ligands attached to the first nanoparticle portion to promote interparticle binding; and (b) a second injectable composition comprising second self-assembling nanoparticles which comprise (i) a second nanoparticle portion and (ii) second interparticle binding ligands attached to the second nanoparticle portion that preferentially bind to the first interparticle binding ligands of the first nanoparticles upon injection of the second composition into the body, wherein said first and second nanoparticle portions can be formed from the same or different materials.
25. The kit of claim 4, wherein said second self-assembling nanoparticles further comprise tissue binding ligands attached to the second nanoparticle portion that cause preferential binding of the second nanoparticles to tissue at said one or more target locations upon injection into the body.
26. The kit of claim 4, wherein said second self-assembling nanoparticles do not further comprise tissue binding ligands attached to the second nanoparticle portion.
27. The kit of claim 4, further comprising a third injectable composition comprising third self-assembling nanoparticles which comprise the following: (i) a third nanoparticle portion and (ii) third interparticle binding ligands attached to the third nanoparticle portion that preferentially bind to the second interparticle binding ligands of the second nanoparticles upon injection into the body, wherein said third self-assembling nanoparticles do not further comprise tissue binding ligands attached to the third nanoparticle portion, wherein said first, second and third nanoparticle portions can be formed from the same or different materials, and wherein said first and third interparticle binding ligands can be the same or different.
28. The composition of claim 6, wherein said organic nanoparticle portions comprise protein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/211,809 | 2005-08-25 | ||
US11/211,809 US20070048383A1 (en) | 2005-08-25 | 2005-08-25 | Self-assembled endovascular structures |
PCT/US2006/033633 WO2007025274A2 (en) | 2005-08-25 | 2006-08-25 | Self-assembling nanoparticles for the treatment of vascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2622904A1 true CA2622904A1 (en) | 2007-03-01 |
Family
ID=37772521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002622904A Abandoned CA2622904A1 (en) | 2005-08-25 | 2006-08-25 | Self-assembling nanoparticles for the treatment of vascular diseases |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070048383A1 (en) |
EP (1) | EP1928434A2 (en) |
JP (1) | JP2009506074A (en) |
CA (1) | CA2622904A1 (en) |
WO (1) | WO2007025274A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077231B2 (en) | 2010-05-25 | 2021-08-03 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
GB0329654D0 (en) * | 2003-12-23 | 2004-01-28 | Smith & Nephew | Tunable segmented polyacetal |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
JP5059312B2 (en) * | 2005-09-16 | 2012-10-24 | Hoya株式会社 | Highly dispersible calcium phosphate compound nanoparticles and method for producing the same |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US20090104433A1 (en) * | 2006-05-18 | 2009-04-23 | Jifan Li | Materials having variable electrical properties based upon environmental stimuli |
EP2061434A2 (en) * | 2006-09-08 | 2009-05-27 | The Regent of the University of California | Engineering shape of polymeric micro-and nanoparticles |
DE602007011671D1 (en) * | 2006-11-30 | 2011-02-10 | Smith & Nephew Inc | FIBER REINFORCED COMPOSITE MATERIAL |
US8372427B2 (en) * | 2007-03-05 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Therapeutic composition with enhanced endothelium targeting |
US20100021985A1 (en) * | 2007-03-20 | 2010-01-28 | The Regents Of The University Of California | Mechanical process for creating particles in fluid |
WO2008115550A1 (en) * | 2007-03-20 | 2008-09-25 | The Regents Of The University Of California | Mechanical process for creating particles in a fluid |
AU2008240418B2 (en) | 2007-04-18 | 2013-08-15 | Smith & Nephew Plc | Expansion moulding of shape memory polymers |
ATE505220T1 (en) | 2007-04-19 | 2011-04-15 | Smith & Nephew Inc | GRAFT FIXATION |
EP2142227B1 (en) | 2007-04-19 | 2012-02-29 | Smith & Nephew, Inc. | Multi-modal shape memory polymers |
WO2009012443A1 (en) * | 2007-07-18 | 2009-01-22 | The Board Of Trustees Of The University Of Illinois | Nanoparticles for the elution of growth factors for recovery and regeneration of organs |
US20090043276A1 (en) * | 2007-08-09 | 2009-02-12 | Boston Scientific Scimed, Inc. | Drug delivery device, compositions and methods relating thereto |
US20090047318A1 (en) * | 2007-08-16 | 2009-02-19 | Abbott Cardiovascular Systems Inc. | Nanoparticle-coated medical devices and formulations for treating vascular disease |
US8722623B2 (en) * | 2007-09-17 | 2014-05-13 | University Of Maryland, Baltimore | Compositions and methods utilizing fibrin beta chain fragments |
US9216220B2 (en) * | 2008-04-10 | 2015-12-22 | Board Of Regents, The University Of Texas System | Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles |
US20110177154A1 (en) * | 2008-09-15 | 2011-07-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Tubular nanostructure targeted to cell membrane |
US20100068523A1 (en) * | 2008-09-16 | 2010-03-18 | Aveka, Incorporated | Surface modification of and dispersion of particles |
ES2335852B1 (en) * | 2008-10-02 | 2011-02-28 | Universidad De Sevilla | USE OF NANOPARTICULES OF NOBLE METALS AS IMMUNOMODULATORS AND IMMUNOMODULATING COMPOSITION. |
CA2740125A1 (en) | 2008-10-09 | 2010-04-15 | Northeastern University | Multifunctional self-assembling polymeric nanosystems |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9457128B2 (en) | 2012-09-07 | 2016-10-04 | President And Fellows Of Harvard College | Scaffolds comprising nanoelectronic components for cells, tissues, and other applications |
US9786850B2 (en) * | 2012-09-07 | 2017-10-10 | President And Fellows Of Harvard College | Methods and systems for scaffolds comprising nanoelectronic components |
US20160220734A1 (en) * | 2013-10-02 | 2016-08-04 | The Regents Of The University Of Colorado, A Body Corporate | Photo-active and radio-opaque shape memory polymer-gold nanocomposite materials for trans-catheter medical devices |
US10182985B2 (en) * | 2014-06-11 | 2019-01-22 | Massachusetts Institute Of Technology | Residence structures and related methods |
AU2015327812B2 (en) | 2014-10-03 | 2021-04-15 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
US10463871B2 (en) | 2015-02-25 | 2019-11-05 | Weinberg Medical Physics Inc | Apparatus and method for medical image-guided 3-D printing within a body |
CN108472249A (en) | 2015-10-23 | 2018-08-31 | 林德拉有限公司 | Stomach resident system and its application method for therapeutic agent sustained release |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2017336154B2 (en) | 2016-09-30 | 2023-11-09 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
WO2018195210A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
WO2020190590A1 (en) * | 2019-03-15 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Monocyte-selective drug delivery system using single-walled carbon nanotubes to induce efferocytosis |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5780010A (en) * | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
EP0975691B1 (en) * | 1997-04-21 | 2010-10-13 | California Institute Of Technology | Multifunctional polymeric coatings |
CA2288292A1 (en) * | 1997-04-24 | 1998-10-29 | Nycomed Imaging As | Embolus therapy using insoluble microparticles or vesicles containing contrast agents |
GB9721901D0 (en) * | 1997-10-16 | 1997-12-17 | Univ Manchester | Particles |
DK1062278T3 (en) * | 1998-02-23 | 2006-09-25 | Mnemoscience Gmbh | Polymers with shape memory |
DE59914547D1 (en) * | 1998-07-15 | 2007-12-20 | Max Planck Gesellschaft | POLYELECTROLYTHOULES ON BIOLOGICAL TEMPLATES |
AU777844B2 (en) * | 1999-04-16 | 2004-11-04 | Children's Medical Center Corporation | Adhesion modulatory peptides and methods for use |
DE60000622T2 (en) * | 1999-06-10 | 2003-02-27 | Max Planck Gesellschaft | ENCLOSURE OF CRYSTALS WITH A MULTILAYER COATING |
ES2263485T3 (en) * | 1999-09-14 | 2006-12-16 | Biogen Idec Ma Inc. | THERAPY FOR CHRONIC RENAL INSUFFICIENCY USING ONE OR MORE INTEGRIN ANGTAGONISTS. |
DE10001172A1 (en) * | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templating solid particles with polymer multilayers |
AU2001231099A1 (en) * | 2000-01-24 | 2001-07-31 | Smart Therapeutics, Inc. | Thin-film shape memory alloy device and method |
US20020043456A1 (en) * | 2000-02-29 | 2002-04-18 | Ho Ken K. | Bimorphic, compositionally-graded, sputter-deposited, thin film shape memory device |
US20040146862A1 (en) * | 2000-03-15 | 2004-07-29 | Eos Biotechnology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US6790298B2 (en) * | 2000-07-10 | 2004-09-14 | Tini Alloy Company | Method of fabrication of free standing shape memory alloy thin film |
ATE273067T1 (en) * | 2000-08-02 | 2004-08-15 | Max Planck Gesellschaft | POLYELECTROLYTE CAPSULE PRODUCTION BY SURFACE PRECIPITATION |
ATE295156T1 (en) * | 2000-08-28 | 2005-05-15 | Max Planck Gesellschaft | MULTI-LAYER POLYELECTROLYTE CAPSULES WITH CONTROLLED AND SUSTAINED RELEASE |
US6805904B2 (en) * | 2002-02-20 | 2004-10-19 | International Business Machines Corporation | Process of forming a multilayer nanoparticle-containing thin film self-assembly |
US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US6746890B2 (en) * | 2002-07-17 | 2004-06-08 | Tini Alloy Company | Three dimensional thin film devices and methods of fabrication |
US7588825B2 (en) * | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
WO2004063705A2 (en) * | 2003-01-08 | 2004-07-29 | University Of Massachusetts | Liquid-liquid interfacial nanoparticle assemblies |
US20040191517A1 (en) * | 2003-03-26 | 2004-09-30 | Industrial Technology Research Institute | Self-assembling nanowires |
ES2293243T3 (en) * | 2003-04-02 | 2008-03-16 | Turun Yliopisto | NANOPARTICULA FOR BIOAFINITY TESTS. |
FI20030615A0 (en) * | 2003-04-24 | 2003-04-24 | Marko Virta | Nanoparticle for Bioaffinity Assays |
US7364585B2 (en) * | 2003-08-11 | 2008-04-29 | Boston Scientific Scimed, Inc. | Medical devices comprising drug-loaded capsules for localized drug delivery |
US20050238870A1 (en) * | 2004-04-22 | 2005-10-27 | Marcia Buiser | Embolization |
US7767220B2 (en) * | 2004-04-23 | 2010-08-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical articles having covalently modified, biocompatible surfaces |
US20060140871A1 (en) * | 2004-11-30 | 2006-06-29 | Sillerud Laurel O | Magnetic resonance imaging of prostate cancer |
-
2005
- 2005-08-25 US US11/211,809 patent/US20070048383A1/en not_active Abandoned
-
2006
- 2006-08-25 JP JP2008528244A patent/JP2009506074A/en active Pending
- 2006-08-25 CA CA002622904A patent/CA2622904A1/en not_active Abandoned
- 2006-08-25 WO PCT/US2006/033633 patent/WO2007025274A2/en active Application Filing
- 2006-08-25 EP EP06802522A patent/EP1928434A2/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077231B2 (en) | 2010-05-25 | 2021-08-03 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
US11173231B2 (en) | 2010-05-25 | 2021-11-16 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
Also Published As
Publication number | Publication date |
---|---|
JP2009506074A (en) | 2009-02-12 |
EP1928434A2 (en) | 2008-06-11 |
WO2007025274A3 (en) | 2007-07-26 |
WO2007025274A2 (en) | 2007-03-01 |
US20070048383A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070048383A1 (en) | Self-assembled endovascular structures | |
JP6714043B2 (en) | Insertable medical device having an elastic substrate on which microparticles are arranged, and drug delivery method | |
JP5139060B2 (en) | Medical device having multiple layers | |
EP2089070B1 (en) | Medical devices having porous regions for controlled therapeutic agent exposure or delivery | |
ES2368125T3 (en) | BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS. | |
US7364585B2 (en) | Medical devices comprising drug-loaded capsules for localized drug delivery | |
EP1965842B1 (en) | Medical devices having multiple charged layers | |
US20050220853A1 (en) | Controlled delivery of therapeutic agents from medical articles | |
US20110014264A1 (en) | Medical Devices Having Nanostructured Regions For Controlled Tissue Biocompatibility And Drug Delivery | |
US20090048659A1 (en) | Medical devices having sol-gel derived ceramic regions with molded submicron surface features | |
US20060088567A1 (en) | Method of manufacturing a medical device having a porous coating thereon | |
EP1688155A1 (en) | Cell growth-inhibiting film, medical instrument and stent for digestive organs | |
JP2009525808A (en) | Balloon catheter with nanotubes | |
Caves et al. | The evolving impact of microfabrication and nanotechnology on stent design | |
EP2205292B1 (en) | Therapeutic agent-eluting medical devices having textured polymeric surfaces | |
Dizaj et al. | The application of nanomaterials in cardiovascular diseases: A review on drugs and devices | |
JP2013526933A (en) | Internal prosthesis | |
Jain et al. | Nanocardiology | |
A Stout et al. | Novel Nano Drug Systems for Cardiovascular Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |